Molecular characterization for oncogenic human papillomaviruses. by Tam, On Yi Ann. & Chinese University of Hong Kong Graduate School. Division of Microbiology.
Molecular Characterization for 
Oncogenic Human 
Papillomaviruses 
TAM On Yi Ann 
A Thesis Submitted in Partial Fulfilment 
of the Requirements for the Degree of 
Master of Philosophy 
in 
Microbiology 
© The Chinese University of Hong Kong 
April 2006 
The Chinese University of Hong Kong holds the copyright of this thesis. Any 
person(s) intending to use a part or whole of the materials in the thesis in "a proposed 
publication must seek copyright release from the Dean of the Graduate School 




Cervical cancer is the second most common cancer in women world-wide. It 
has been confirmed that human papillomavirus (HPV) is associated with cervical 
cancer. Currently, more than 100 different types of HPVs have been characterized 
and they are divided into low- and high-risk groups. World-wide, HPV 16 remains 
the most common type that found in cervical cancer, followed by HPV 18，31, 33，52 
and 58. However, variation in genotype distribution exists among different 
geographical regions and ethnic groups. 
Study I. Comparison of three different HPV detection methods. This study 
examined the influence of detection methods on assessing the prevalence of HPVs 
and thus the potential effects on prioritizing oncogenic HPV types as vaccine 
candidates. A total of 120 cervical biopsies (105 fresh frozen and 15 
paraffin-embedded) collected from Hong Kong Chinese women aged between 26-84 
years were examined. All samples were examined in parallel by the three common 
HPV detection methods. Method one: GP5+/6+ PGR followed by DNA sequencing, 
method two: MY09/11 PGR followed by restriction fragment length polymorphism, 
and method three: PGMY09/11 PGR followed by reverse line-blot hybridization 
assay. According to the results, the PGMY09/11 method was found to be the most 
superior in sensitivity with a positive rate of 96%. Overall, HPV 52 was 
under-estimated when using GP5+/6+ as the detection tool. The prevalence order 
of HPV infection in cervical cancer was HPV 16 (50%), HPV 18 (21.7%), HPV 52 
(12.5%), HPV 58 (8.3%), and HPV 33 (5.0%). When HPV genotype distribution in 
Hong Kong was compared to other parts of the world, two world-wide uncommon 
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HPV types - HPV 52, 58 were found with a higher prevalence in Hong Kong women 
with cervical cancer. The results of this study are important in vaccine candidate 
selection and development. 
Study II. Post-treatment follow-up study on patients with high-grade 
cervical lesions. This study investigated the prevalence and genotype distribution 
of HPV infection in patients with high-grade squamous intraepithelial lesions, and 
the relationship between HPV persistence and recurrence of cervical lesions 
following local surgical treatment. A total of 202 patients that had undergone loop 
electrosurgical excision procedure (LEEP), aged between 25-62 years were recruited 
in this study. Four hundred and four cervical scrapes collected before and 
12-months after LEEP were examined. HPV DNA was detected by the reverse 
line-blot hybridization assay. Cytological results showed that 24% (49/202) of 
patients had cervical intraepithelial neoplasia grade II (CIN II) and 76% of (152/202) 
patients had CIN III before LEER At 12-months after LEEP, two patients were 
confirmed to have CIN recurrence by colposcopic and histopathological 
examinations. 
Our results showed that the six most common HPV infections of patients with 
� high-grade cervical lesions were HPV 16 (34%), HPV 52 (19%), HPV 58 (11%), 
HPV 18 (9%), HPV 33 (8%), and HPV 31 (5%). HPV 52 and 58 are the second and 
third common HPV genotypes found in patients with high-grade cervical lesions. 
These unusual high prevalence rates of HPV 52 and 58 support the findings in study 
I. Both of them have a high priority as a vaccine candidate for Hong Kong. 
The results of this study also showed that all patients with CIN recurrence had 
II 
both involved excision margin and persistent HPV infection. Therefore, HPV DNA 
testing may play a role in detecting residual lesions. However, because the number 
of patients with CIN recurrence in this current study was too small for statistical 
analysis, the relationship between persistent HPV infection and recurrence of 
cervical lesions following local surgical treatment cannot be assessed. 
Study III. Investigation of human papillomavirus 52 sequence variation. 
Results from study I and II showed that the relatively high prevalence rate of HPV 52 
in Hong Kong was different to other geographic regions, which led us to study if 
there may be any genetic variation in HPV 52 in Hong Kong. In this study, a total 
of 66 cervical neoplasia specimens collected from Hong Kong Chinese women aged 
25-84 years were examined. Human papillomavirus E6 and E7 genes, which 
encode oncogenic proteins, were analysed by sequencing. According to the results, 
a total of 12 non-prototype-like HPV 52 E6 variants and five non-prototype-like 
HPV 52 E7 variants were found. Among the 26 nucleotide substitutions, four 
nucleotide substitutions of E6 and six nucleotide substitutions of E7 substitutions 
were non-synonymous. Although there were no significant associations between 
HPV 52 E6/E7 variants and the severity of cervical neoplasia, these results are 
important in understanding the oncogenic risk association of different variants and 


















而HPV感染的流行程度的順序排列爲HPV 16型(50%)，HPV 18型(21.7%)，HPV 
52 型(12.50/0) ’ HPV 58 型(8.3%)和 HPV 33 型(5.0%) ° 在 HPV 基因型在香港及 
全球的分佈比較中發現，HPV 52型和HPV 58型在香港較爲流行。此發現對 
HPV疫苗的發展和候選疫苗型號的選擇有重要影響。 
、 第二項硏究是對患有高度鱗狀皮下病變（high-grade squamous intraepithelial 
lesions，簡稱HGSIL)的病人，手術後進行的覆檢之硏究。此硏究調查於患有 
HGSIL的病人中HPV的發病率和基因型的分佈，及HPV長期感染跟手術後子 








別爲 HPV 16 型(34%)，HPV52 型(19%)，HPV58 型(11%)’ HPV 18 型(9o/o)， 











HPV E6變體和9種非常見型的HPV E7變體°在29個驗基替換中，8個E6和 
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“ M phase mitosis phase 
MCM minichromosome maintenance .. 
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nt nucleotide 
OR , odds ratio 
VIII 
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p probability 
Pap Papanicolaou 
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pM pico molar 
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S phase synthesis phase 
SD standard deviation 
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1.1 History of human papillomavirus 
For more than 100 years, scientists have recognized that cervical cancer, which 
is the second most prevalent malignancy in women world-wide, is caused by a 
sexually transmitted agent. Before the development of recombinant DNA 
technology, herpes simplex virus was assumed to be the culprit. However, in 1955, 
Koss and Durfee became the first to describe the unusual structure of the squamous 
cells associated with these lesions (large cells with exaggerated, hyperchromatic 
nuclei and an often sharply demarcated perinuclear clear zone), which they termed 
"koilocytotic atypia" or "koilocytosis," from the Greek koilos, meaning hollow (Koss 
and Durfee 1955). 
Because human papillomavirus (HPV) cannot be grown in cell culture, detailed 
analysis was impossible until cloning techniques were developed in the 1970s. 
Finally, in the mid-1980s, a German research team led by zur Hausen (Tsunokawa, 
Takebe et al 1986) succeeded in cloning the most important oncogenic viral type -
HPV 16，which they then generously distributed to laboratories throughout the world. 
Initially, there was considerable resistance to the idea that HPV rather than herpes 
simplex vims was the aetiologic agent, particularly since early studies employed a 
• crude filter in-situ hybridization test that occasionally failed to reveal virus that was 
present in tissue samples. More recent studies using Southern blot hybridization or 
polymerase chain reaction (PGR) have confirmed that the causal relation between 
HPV and cervical intraepithelial neoplasia is in fact extremely strong (Walboomers, 
Jacobs et al 1.999; Bruck, Zee et al. 2005). 
Using the most sensitive detection method, HPV infection was found in 99.7% 
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of patients with cervical cancer (Franco, Rohan et al 1999). Although other 
independent risk factors probably exist, HPV is considered the driving force behind 
the dysregulation of the cell cycle that underlies malignant transformation. 
Confirmation of this is provided by 1) molecular evidence that HPV oncoproteins E6 
and E7 can induce malignant changes in animal models and cultured cells, 2) cohort 
studies showing that persistent HPV infection increases the risk of high-grade 
cervical intraepithelial neoplasia, and 3) data demonstrating a correlation between 
resolution of HPV infection and regression of cervical lesions. 
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1.2 Biology of human papillomavirus 
1.2.1 Classification 
Human papillomavirus was previously classified to belong to the subfamily 
papillomavirus (together with polyomavirus) of the papovaviridae family (both 
groups of viruses have capsids with similar structure and contains a double-stranded, 
circular, covalently closed DNA genome). In recent years, papillomaviruses have 
been formally recognized as a family of their own, the papillomaviridae family (de 
Billers 2001). 
The classification of papillomaviruses is based on sequence similarity in the E6, 
E7 and LI regions. A new HPV type is defined by less than 90% sequence 
similarity with previously identified types with respect to these regions (Bonnez 
1993). Human papillomaviruses have further been classified into subtypes, when 
they have 90 to 98% sequence similarity to the corresponding type and classified into 
variants when they show no more than 2% sequence variation to the prototype. 
Until now, more than 200 types of HPV have been recognized. Eighty-five of 
* them are well characterized, whereas the other 120 isolates are partially characterized 
potential new genotypes (zur Hansen 1999). 
The sequence similarities in the E6, E7 and LI genes also helped to identify 
groupings of related HPVs. At the level of greatest diversity (major branches), five 
supergroups of papillomaviruses can be distinguished, of which three contain HPVs 
(supergroups A, B and E) (Bernard 2005). 
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The largest supergroup A includes 44 HPV types and seven additional but 
un-typed genomes. Eleven groups can be distinguished within supergroup A, most 
of which unite phenotypically and pathologically similar HPV types. One of these 
groups contains HPV 16，31，33 and 35 and another contains HPV 18 and 45, the 
HPV types most frequently reported in association with malignant genital lesions. 
Yet another group contains HPV 6 and 11，which induce genital warts and other 
benign genital lesions as well as laryngeal papillomas. 
Human papillomavirus can also be classified according to the site of infection, 
cutaneous types or mucosal types. Cutaneous types of HPV are epidermotrophic 
and target the skin of the hands and feet. Mucosal types infect the lining of the 
mouth, throat, respiratory tract, or anogenital epithelium. Benign lesions include 
common warts (verruca vulgaris), plantar warts, genital warts (condyloma 
acuminate), lesions of the mouth, nose and throat, conjunctival papillomatosis, and 
cervical intraepithelial neoplasias. 
1.2.2 Genome structure 
Human papillomavirus is a relatively small, non-enveloped virus, 55 nm in 
diameter. It has an icosahedral capsid composing of 72 capsomers, which contains 
at least two capsid proteins, LI and L2 (Baker, Newcomb et al. 1991). Each 
capsomer is a pentamer of the major capsid protein, LI. Each virion capsid 
contains several copies (about 12 per virion) of the minor capsid protein, L2 (Sapp, 
Volpers et <2/, 1995). The virus is said to somewhat resemble a "golf ball" when 
viewed by electron microscopy. 
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The HPV genome consists of a single molecule of circular, double-stranded 
DNA containing approximately 8,000 bp associated with histones (Favre 1975). All 
open reading frame (ORF) sequences are restricted to one strand, and so transcription 
is restricted on one strand. The genome of HPV is functionally divided into three 
regions. The first region is an upstream regulatory region of 400 to 1,000 bp, which 
has been referred to as the non-coding region. This region contains the p97 core 
promoter along with enhancer and silencer sequences that regulate DNA replication 
by controlling the transcription of the ORFs. This region also contains the highest 
degree of variation in the viral genome (Apt, Watts et al 1996). The second region 
is an early region, consisting of ORFs El, E2, E4, E5, E6, and E7, which are 
involved in viral replication and oncogenesis. The last region is a late region, 
which encodes the LI and 12 structural proteins for the viral capsid. LI gene 
encodes the major capsid protein and L2 gene encodes the minor capsid protein 
(Frattini, Lim et al 1996). 
1.2.3 Properties of gene products 
1.2.3.1 El gene 
. The El gene encodes a phosphoprotein of approximately 68 kDa with intrinsic 
helicase, ATPase, and specific DNA-binding ability (Lusky and Fontane 1991). 
The El protein, in association with E2, is essential for viral replication, and it is 
thought that the E1-E2 complex binds through E2 to specific sites in the upstream 
regulatory region, stabilizing El in a conformation which recognizes the viral origin 
of replication for the initial steps in viral DNA replication (Berg and Stenlund 1997). 
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1.2.3.2 E2 gene 
The E2 gene has several functions which include the positive and negative 
regulations of gene expression (Ham, Dostatni et al 1991). It has recently been 
suggested that E2 can activate the tumour suppressor gene, p53, independently of E6, 
and that E2 expression may result in cell apoptosis (Desaintes, Demeret et al. 1997). 
1.2.3.3 E4 gene 
The function of the E4 protein is yet to be defined. For some HPVs, it is 
transcribed only in terminally differentiated keratinocytes. However, in HPV type 1 
transcription of E4 gene occurs lower down in the epithelium (Doorbar, Coneron et 
al 1989). The interaction between E4 protein and cytokeratins may induce collapse 
of the intermediate cellular network, resulting in koilocyte formation (Doorbar, 
Evans et al 1988; Berg and Stenlund 1997). 
1.2.3.4 E5 gene 
This gene is absent in some HPVs and truncated in others. E5 has been shown 
to have a transforming function in HPV 1，6, and 16 (Chen and Mounts 1990; 
Crusius, Anvinen et al. 1997) and may be capable of acting in cooperation with 
epidermal growth factor to induce cellular proliferation (Pirn, Collins et al. 1992). 
1.2.3.5 E6 gene 
The E6 protein plays a key role in cellular transformation, partly through 
inactivation of cellular tumour suppressing protein p53. Interestingly, the 
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oncogenic potential of different HPV types correlates with the binding affinity of 
their E6 proteins. E6 has been reported to act in conjunction with E6-associated 
protein (E6-AP) to degrade p53. Reduction of E6-AP in HPV infected cells 
produces increased levels of p53, whereas reduction in normal cells has no effect on 
p53 levels (Beer-Romero, Glass et al. 1997). 
E6 protein has also recently been shown to interact with cellular 
minichromosome maintenance (MCM) proteins (Pirn, Massimi et al 1997)，which 
are believed to play a key role in regulating cellular DNA replication. Other 
potential transformation related functions of E6 include telomerase activation 
(Stoppler, Hartmann et al. 1997)，paxillin binding (Tong and Howley 1997), 
transactivation of the c-myc promoter (Kinoshita, Shirasawa et al. 1997), and 
upregulation of epidermal growth factor receptor (Baker, Newcomb et al 1991). 
1.2.3.6 E7 gene 
E7 proteins also play an important role in cell transformation, with different 
domains of the E7 gene sequence appearing to determine transformation and 
transactivation. E7 protein interacts with the tumour suppressing retinoblastoma 
. ( R b ) gene proteins and promotes Rb protein degradation through a 
ubiquitin-proteasome pathway (Phillips and Vousden 1997). Decreased stability of 
Rb protein mediated by E7 could have multiple effects on the control of cell cycle 
progression. Numerous cell cycle regulatory protein targets of HPV E7 have now 
been identified which include p21, the closely related kinase inhibitor p27, cyclin A, 〜， 
TATA binding protein, and members of the AP-1 transcription factor family 
(Zerfass-Thome, Zwerschke et al 1996; Massimi and Banks 1997). 
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1.2.3.7 LI and L2 genes 
The two "late" genes extend over almost half of the HPV genome and encode 
the two viral capsid proteins. The L2 region appears to be important in virus-host 
cell interactions (Cossart, Thompson et al. 1995). 
Transcription of the viral genome is very complex with some RNA spliced and 
some ORF spliced together to encode fusion proteins, whilst others encode multiple 
products. Transcription of HPV genes is tightly co-ordinated with the 
differentiation of epithelial cells. Using in-situ hybridization, one sees different 
RNA transcripts within the different epithelial cell layers and complete virions are 
only seen in the upper terminally differentiated epithelial cells. 
1.2.4 Latent and lytic life cycle 
The productive life cycle of HPVs is directly linked to the epithelial cell 
differentiation. Following the entry into keratinocytes in the basal layer, HPV 
genomes are established as episomes at approximately 50 copies per cell, which 
replicate in synchrony with the cellular DNA replication (Stubenrauch and Laimins 
.1999). The establishment and maintenance of HPV genomes are associated with 
expression of early HPV transcripts that encode the oncoproteins E6, E7, and E5 as 
well as the replication proteins El and E2. Following cell division, infected 
daughter cells leave the basal layer, migrate towards the superbasal regions and begin 
to differentiate. In contrast to un-infected keratinocytes, which exit the cell cycle as 
soon as they detach from the basement membrane, HPV-infected cells enter into S 
phase after reaching'the superbasal layer (Doorbar, Foo et al. 1997). This entry into 
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S phase results in amplification of the viral genomes to thousands of copies per cell. 
Concurrent with the viral DNA amplification is the synthesis of El, E4 proteins 
along with capsid proteins resulting in the assembly of infectious virions. 
Subsequently, virions are released into the environment as the upper layer of the 
epithelium is shed (Lambert 1991). 
In low-grade cervical lesions, the HPV genomes are found exclusively as 
episomal DNA molecules. In contrast, in cervical carcinomas, high-risk HPV 
genomes are often found integrated into the cellular host DNA (Schwarz, Freese et al 
1985). Human papillomavirus DNA integration has been suggested to be an 
important event in the development of cervical cancer, since this often results in the 
disruption of the E2 region (Stoler, Rhodes et al. 1992). Integration thus abrogates 
the inhibitory actions of the E2 proteins on the viral promoter of the E6 and E7 genes. 
This results in high-level expression of E6 and E7, and most likely contributes to 
cellular transformation that eventually results in cancer (Schneider-Gadicke and 
Schwarz 1986; Baker, Phelps et al 1987). Details will be discussed in the next 
section. 
.1.2.5 Host specificity 
In general, papillomavirus is considered as highly species-specific, with each 
species having its own papillomavirus, for example, bovine papillomaviruses (BPV) 
of cattle and cotton tail rabbit papillomavirus (CRPV) of rabbit (Jarrett 1985). 
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1.2.6 Site of infection 
Epithelial cells are the target region for HPV infection, with the exception of the 
ungulate-specific fibro-papillomavimses (e.g. BPV-1) which also infect dermal 
fibroblasts, they are restricted to this target cell population. The mechanism for this 
restriction is not clear since papillomavirus particles attach to and are taken up by 
cells derived from different tissues and different species (Roden, Kimbauer et al. 
1994; Muller, Gissmann et al. 1995). Epithelial-specific transcription activation is 
likely to play an important role in the selection of epithelial target cells (Cripe, 
Haugen et al. 1987; Gloss, Bernard et al 1987). 
1.2.7 Clinical manifestations 
HPV was first recognized as the cause of cutaneous warts (plantar warts, 
common warts, flat warts) on the hands and feet. Warts are areas of hypertrophied 
skin filled with keratin and are considered to be mainly a cosmetic nuisance; 
generally, they resolve spontaneously within one to five years. The most common 
HPV types found in benign skin lesions are HPV 1 to 4 (Chang, Syrjanen et al 2000). 
However, other strains that grows primarily in the lining of the mouth produce small 
-elevated nodules that can develop into fatal squamous cell cancers. Focal epithelial 
hyperplasia of the oral cavity (Heck's disease) is caused predominantly by HPV 13 
and tends to regress spontaneously. HPV is also associated with epidermodysplasia 
verruciformis (EV), a genetic disease in which patients develop skin cancer after 
exposure to si^nlight. HPV types 2，3，5, 8，9, 10, 12, 14，15, 17 are the most 
frequently associated types of this disease (Majewski, Malejczyk et al 1990). 
Susceptibility to these HPV types is believed to be secondary to a defect in 
11 
cell-mediated immunity (Majewski and Jablonska 1995). Epidermodysplasia 
verruciformis manifests in childhood with lesions on the back, chest, and limbs. 
These lesions undergo oncogenesis in 25% to 63% of cases, especially on areas of 
the skin exposed to sunlight (Lutzner, Blanchet-Bardon et al. 1984). However, only 
a few EV-related types (most notably HPV 5 and 8) seem to have oncogenic potential 
(Yutsudo and Hakura 1987). Most EV-related HPV types also have been found to 
cause lesions in immuno-compromised hosts (Lutzner, Orth et al. 1983; Barr, Benton 
et al. 1989). Another disease associated with HPVs is recurrent respiratory 
papillomatosis, it is primarily a disease of the larynx in young children at a median 
age of three years but can also occur in adults (Shykhon, Kuo et al. 2002). Because 
a high percentage of mothers has a history of HPV and because similar HPV types (6’ 
11) cause anogenital warts and recurrent respiratory papillomatosis, the infection in 
young children is thought to be acquired by passage through an infected birth canal. 
There are also some suggestions that the disease may be acquired in-utero since 
cases have been documented at birth after cesarean section (Murray and Miller 1998). 
Respiratory tract lesions may undergo malignant transformation. 
1.2.8 Mode of infection 
Clinical and subclinical HPV infections are the most common 
sexually-transmitted disease today. Asymptomatic cervical HPV infection can be 
detected in 5-40% of women of reproductive age (Parkin, Bray et al. 2001). Human 
papillomavirus infection is a transient or intermittent phenomenon, only a small 
proportion of women positive for a given HPV type are found to have the same type 
in subsequent specimens (Morrison 1994; Piyathilake, Henao et al. 2004). Risk of 
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subsequent cervical intraepithelial neoplasia (CIN) is proportional to the number of 
specimens testing positive for HPV (Jin, Cash et al. 1999)，which suggests that 
carcinogenic development results from persistent infections. 
1.2.9 Detection method 
Currently, most therapeutic decisions regarding HPV testing are made based on 
colposcopic, cytological or histopathological examinations. It can be argued that 
detection and typing of HPV add little to the decision-making process (Roman and 
Fife 1989). HPV testing may be helpful in patients with a cervical lesion that is 
mildly atypical or shows low-grade dysplasia (Cox, Lorincz et al. 1995). Women 
with a high-risk HPV type may deserve more aggressive management than those 
with a low-risk type (Schiffman and Brinton 1995a). As more studies applying 
HPV testing to large populations of women in cervical cancer screening programs are 
completed, more specific recommendations can be made. HPV testing can also 
used as an adjunct to cervical cytology screening. One study showed that adding 
HPV testing to cytology identified a number of women with high-grade lesions on 
cervical biopsy who had normal or minimally abnormal screening cervical cytology 
(Cuzick, Szarewski et al 1995). 
1.2.9.1 DNA hybridization 
In the past, Southern blot is the method of choice for the diagnosis of HPV. 
Deoxyribonucleic acid (DNA) is extracted from a clinical specimen and digested 
with a site-specific restriction endonuclease. The fragments are separated by 
electrophoresis, transferred to a membrane, and hybridized with labelled HPV DNA 
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probe. This method detects specific HPV types based on the fragment pattern and 
reaction with individual probes. Using low-stringency hybridization conditions, 
HPV types other than those in the probe mixture can also be detected because some 
regions of DNA sequence homology exist among all papillomaviruses. 
Despite the reliability of Southern blot, it has significant limitations. A 
relatively large amount of DNA is required, making it difficult to do a Southern blot 
on any specimen other than tissue. Exfoliated cells of the cervix (or other sites) 
often do not yield enough DNA for Southern blot analysis. In addition, the method 
is relatively insensitive, detecting only about 0.1 to 0.5 copies of HPV DNA per cell 
(Cuzick, Terry et al 1992). It is even less sensitive at detecting heterologous HPV 
types under low-stringency conditions. In addition, the method is cumbersome and 
labour-intensive and thus impractical for large screening studies or in clinical 
diagnosis. Southern blot is neither fully standardized nor FDA approved as a 
commercial diagnostic test. 
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1.2.9.2 DNA amplification methods 
Owing to the large number of HPV types, a relatively non-selective method of 
HPV identification is most useful. Despite the many types, all HPVs have regions 
of DNA that show significant nucleotide sequence homology (Danos, Engel et al. 
1983). One of these conserved regions is in the LI major capsid protein gene. It 
has been possible to design consensus PGR primers containing a variety of sequences 
that permits amplification of any genital HPV type with high efficiency (Manos, Ting 
et al. 1989). 
Although other consensus primer systems have been developed (Baay, Quint et 
al. 1996), the LI system has received the widest use. Because LI consensus primer 
PGR assay is the most sensitive test for HPV available, far exceeding the sensitivity 
of the Southern blot method (Schiffman, Bauer et al. 1991). In addition to detecting 
the presence of HPV DNA, this assay can also provide typing information using 
type-specific DNA probes that bind to unique regions between the common primers. 
Most studies using this assay, however, still report a number of specimens that are 
positive but cannot be typed. These untypable specimens may represent novel HPV 
types or untypable or uncharacterized DNA sequence variability among known types. 
• The LI method has not been fully standardized and has not received FDA approval 
for sale as a diagnostic test. 
A recent attempt has been made to provide better standardization and 
reproducibility of the consensus primer PGR assay (Gravitt, Peyton et al. 1998). In 
this format the primers are biotinylated, and the product from the PGR reaction is 
used as a probe for a membrane that contains type-specific sequences for 27 
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commonly identified genital HPV types. Subsequent reaction of the membrane 
with avidin-peroxidase and a peroxidase substrate permits easy identification of areas 
that bind the biotinylated DNA. By carefully manufacturing these membrane strips 
so that the probes are immobilized in exactly the same positions, it is relatively easy 
to align the strip with a reading template and to identify the HPV types amplified. 
The advantage of this method is that the polymerase chain reaction can analyse 
a variety of clinical specimens for HPV DNA. Because the cervix is the usual 
target site for diagnosis, cervical scrapes, cervical swabs, or cervico-vaginal lavage 
specimens are often used. The cells are concentrated and DNA is extracted for the 
PGR assay. DNA from biopsy material can also be extracted for PGR analysis. 
The PGR assay is so sensitive that a section from a fixed and embedded tissue 
specimen can also be used for HPV analysis. 
1.2.9.3 Hybrid capture assay 
Hybrid capture assay is a widely used detection method for clinical diagnosis. 
Specimens (usually from the cervix) are collected on a Dacron swab and placed in a 
solution that lyses the cells and preserves DNA. The key components of the assay 
are ribonucleic acid (RNA) probes for 14 commonly identified genital HPV types 
and a monoclonal antibody that recognizes molecular hybrids formed between RNA 
(the supplied probes) and DNA (viral DNA in the specimen). The test is configured 
to detect HPV DNA according to associated risk of dysplasia. The RNA probes are 
used in two pools, a low-risk group (currently containing HPV 6, 11，42, 43, and 44) � 
and a high-risk group (currently containing HPV 16，18，31，33，35, 45, 51, 52, and 
56). The results are easily interpreted and provide quantitative information, 
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permitting an estimate of the amount of HPV DNA present in the specimen. 
Evidence suggests that the quantity of HPV may have important prognostic 
implications (Morrison, Ho et al. 1991). Because of a standardized protocol, the 
assay also is reproducible between laboratories (Schiffman, Kiviat et al. 1995b). 
The sensitivity of the hybrid capture assay, about 0.05 copies per cell, is intermediate 
between PGR and Southern blot. 
The hybrid capture assay has significant limitations. First, the range of HPV 
types is limited to the 14 types contained in the assay. Although these types are 
among the most prevalent types found in the human genital tract, many genital types 
are not represented in the probe pools used. Some of the other types, including 
uncharacterized types, are relatively common in some series (Shah, Solomon et al. 
1997). This aspect gives PGR a distinct advantage. Second, the hybrid capture 
assay is less sensitive than PGR for the types contained in the probe pools. 
Although this is a disadvantage of the hybrid capture assay, the significance of 
detecting minute quantities of HPV DNA in clinical samples is uncertain. Third, 
the hybrid capture assay requires more DNA for optimal performance than does PCR. 
Most clinical specimens yield sufficient DNA for analysis by either of the method, 
but specimen adequacy is occasionally a problem with the hybrid capture assay. 
1.2.9.4 Other DNA detection methods 
Dot blot assays (Weintraub, Redard et al 1992), reverse blot assays (de Villiers, 
Schneider et al 1986; Webb, Rogers et al. 1987), and tissue in-situ (Beckmann, �‘ 
Myerson et al. 1985; Gupta, Gupta et al. 1987) and filter in-situ (McCance, Campion 
et al. 1986; de Villiers, Wagner et al. 1987) hybridization assays may be helpful 
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under certain circumstances, but none has sufficient sensitivity, specificity, or ability 
to detect novel HPV types to make them generally useful in a clinical setting. So 
they are not recommended for diagnostic applications. 
1.2.9.5 Serology 
Attempts to establish serologic assays for HPV have met with limited success. 
Early studies using recombinant protein antigens were disappointing, but more recent 
efforts using vims-like particles that preserve conformational epitopes have been 
more promising (Carter, Koutsky et al 1996). These assays have demonstrated 
type-specific antibodies in study subjects. In most reports, not all persons with 
clinical disease or detectable HPV DNA were antibody positive, so the sensitivity of 
these tests may still be inadequate. 
One study correlated acquisition of HPV 16 DNA in genital tract specimens 
with the development of HPV 16 antibody and found a significant delay between the 
two events (Wideroff, Schiffman et al. 1996). More than 90% of women who had 
HPV 16 DNA detected on entry into the study had or developed HPV 16 antibody 
over a 16 month period of follow-up. This suggests that most women may 
eventually develop antibody, but the timing may be highly variable. 
Serologic assays are being more thoroughly characterized and may have a more 
clear defined role in HPV diagnosis in the near future. 
18 
1.3 Biology of cervical intraepithelial neoplasia 
and cervical cancer 
Studies have demonstrated that cervical cancer arises as a consequence of 
progression from mild dysplasia through severe dysplasia to carcinoma in-situ and 
carcinoma. Richart (1990) introduced the commonly used classification system for 
the pre-invasive lesions as different grades of cervical intraepithelial neoplasia (CIN 
I to III). CIN I refers to mild dysplasia limited to the basal layers of the epithelium. 
When changes involve two-thirds of the total thickness of the epithelium, the lesion 
is referred to as CIN II. When they involve the whole thickness of the epithelium, it 
is referred to as CIN III. 
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1.3.1 Grading of severity of cervical neoplasia 
A number of different histopathological classification systems have been used to 
describe the evolution of cervical neoplasia and to establish criteria for treatment 
(lARC 1986) (Figure 1.1). The original Papanicolaou (Pap) smear classification 
identified five basic stages: mild, moderate, and severe dysplasia, carcinoma in-situ, 
and cancer. These have been largely superseded by the four-stage classification 
introduced in the late 1960s by Richart, consisting of CIN I，II, and III，followed by 
cancer. However, because neither of these categorizations includes HPV status, 
pathologists began appending "with koilocytosis" or "without koilocytosis" to their 
reports, which was confusing to clinicians. Consequently, the Bethesda system was 
developed in 1988. Under this grading system, all cytological abnormalities are 
classified as either low- or high-grade squamous intraepithelial lesions (LGSIL, 
HGSIL). LGSILs include normal cells with koilocytosis as well as mild dysplasia, 
and HGSILs include moderate-to-severe dysplasia together with carcinoma in situ. 
When smears contain atypical cells that cannot be easily classified, the cells are 
described as atypical squamous cells of uncertain significance (ASCUS). As a 
means of identifying the subset of patients who should be managed more 
aggressively, the Bethesda system works very well. 
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Figure 1.1 Different grading systems of cervical lesions 
Papanicolaou Mild Moderate Severe Carcinoma 广 
(P叩）smear Atypia dysplasia dvsplasia in situ �仙 c c r 
classification ^ * * ‘ 
Ccrvical 
intraepithelial ^IN 丨 CIN 2 CIN 3 Cancer 
neoplasiii 
(CIN) grade 
Ucthijsdsi ASCIIS LGSIL HCSIL Canccr 
system 
CIN I, II or III = cervical intraepithelial neoplasia grade I, II or III, respectively. 
ASCIIS = atypical squamous cells of uncertain significance. LGSIL = low-grade 
squamous intraepithelial lesion, and HGSIL = high-grade squamous intraepithelial 
lesion. (lARC 1986) 
*. 
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1.3.2 Treatment of cervical intraepithelial lesions 
Treatment of pre-cancerous lesion is simple, safe and usually curative (Spitzer, 
Chemys et al. 1993). Treatment is indicated if CIN I involves more than two 
quadrants of the cervix or if the patient is unable or unwilling to return for follow-up, 
or if the lesion persists for more than two years. Treatments are recommended for 
CIN II or CIN III. 
Treatment options include loop electro-surgical excision procedure (LEEP), 
cryosurgery, laser vaporization, cold coagulation and electro-coagulation diathermy. 
Treatment by LEEP is recommended by The Hong Kong College of Obstetricians 
and Gynaecologists as it provides a tissue specimen for histological exclusion of 
occult invasion (HKCOG 2002). After treatment, patients are followed-up by 
cervical cytology for three times at four to six months intervals, then annually for 
five years, and then every three years. 
1.3.3 Prognosis after treatment 
Also, there has been consensus that the widespread and adequate removal of 
pre-malignant lesions prevents the subsequent development of most invasive 
carcinomas which led to a significant reduction in the incidence and mortality rate 
due to cervical cancer (Wright, Koulos et al. 1994). Early detection and treatment 
of cervical pre-malignant changes have been the main contributory factor for cervical 
cancer to decline from the second place to the sixth most common cancer in the UK 
and USA (Cox 1999). A recent analysis of long-term studies of follow-up 
conservative treatment of the pre-malignant stage has shown a reduction in the risk 
of cervical cancer by'95% for at least eight years (Soutter, de Barros Lopes et al 
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1997). 
1.4 Epidemiology of cervical cancer 
1.4.1 Global burden of disease 
Cervical cancer is the second most common cancer in women world-wide, 
accounting for 6% of all malignancies in women. Cervical cancer is preceded only 
by breast cancer as the most common cause of death from cancer in women 
world-wide. There are about 470,000 new cases diagnosed every year, and this 
occurs predominantly among the economically disadvantaged, in both developing 
and industrialized nations, and approximately 230,000 women die from invasive 
cervical cancer every year (Franceschi 2005a). 
In many developing countries, for examples Latin America, sub-Saharan Africa 
and Southeast Asia, cervical cancer is not only the most frequently occurring cancer 
among middle-aged women, but also as a leading cause of death (Mandelblatt, 
Lawrence et al 2002). This is due, in part, to poor access to medical care and the 
unavailability of routine cervical screening in many of these countries. 
1.4.2 Local burden of disease 
1.4.2.1 Incidence 
According to the Hong Kong Cancer Registry in 2001, cervical cancer is ranked 
fifth among female cancers in Hong Kong (after breast, lung, colon and rectal 
cancer). A total of 438 cases of cervical cancer were diagnosed in 2001 (Hospital 
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Authority 2003). Cervical cancer accounts for 4.6% of all new cancers in females. 
The age-standardized incidence rate (according to 1997-99 World Health Statistics 
Annual) was 10.1 per 100 000 women. 
1.4.2.2 Mortality 
Cervical cancer ranked the eighth as a cause of cancer deaths among females 
(after lung cancer, breast cancer, colon cancer, liver cancer, stomach cancer, rectal 
cancer and pancreatic cancer) in Hong Kong in 2001. A total of 128 deaths were 
due to cervical cancer in 2001 (Department of Health 2003a). It accounts for 3.0% 
of all cancer deaths in females. The age-standardized mortality rate (according to 
1997-99 World Health Statistics Annual) was 2.8 per 100 000 standard population. 
The potential years of life lost (PYLL) before 75 years of age due to cervical cancer 
is 1713 accounting for 4.4% of total PYLL before 75 years from all cancers among 
females. 
1.4.2.3 Age distribution 
Cervical cancer is affecting relatively younger women. In 2001, the median 
age at diagnosis of cervical cancer was 52 years which is 13 years earlier than the 
median age at diagnosis of 65 years for all cancers in females (Hospital Authority 
2003). In general, the burden of cervical cancer increases with age. According to 
the Hong Kong Cancer Registry in 2001, both incidence and mortality rates have 
rised sharply after age 25 and reach the peak at the age group 75-79 and 80-84 
respectively. � 
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1.4.2.4 Trends of incidence and mortality 
Since 1997，both trends of incidence and mortality are stably decreasing. 
Factors contributing to these decreasing trends include increased screening programs 
among women in middle-age groups where this downward trend is the most 
significant. In 1983-2001, the age-specific incidence rate of cervical cancer 
decreased by 70.4% for women aged 40-64 years. 
1.4.2.5 Morbidity 
According to the data from Hospital Authority, Hong Kong SAR, 
hospitalization of women with cervical cancer decreased slightly in the 1990s. The 
number of in-patient discharges and deaths from the disease was around 2500 per 
year in the first half of 1990s and decreased by over 20% in year 2001 (Department 
of Health 2003b). 
1.4.2.6 International comparison 
When these local statistics are compared with other developed counties with 
well-established screening programs, Hong Kong is the second in cervical cancer 
incidence rate after Singapore. In 1999，the age-standardized incidence rate per 100 
000 women, adjusted to the World Standard Population, for Singapore and Hong 
Kong was 14.2 and 9.7 respectively (Anderson, Boyes et al 1988; Anttila, Pukkala et 
al 1999). On the other hand, the age-standardized mortality rates in these countries 
ranged from 1.3-2.3 per 100 000 women, which are again substantially below the 
rate in Hong Kong. ‘ 
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1.5 Aetiology and risk factors 
1.5.1 Human papillomavirus infection 
The causal link between certain types of HPV infection and cervical cancer has 
been established (Bosch, Lorincz et al. 2002). Epidemiological studies that 
evaluated risk factors of squamous intraepithelial lesions (SIL) and cervical 
malignancy demonstrated conclusively a sexual mode of transmission of a 
carcinogen. It is now widely accepted that HPV is strongly implicated 
epidemiologically as the primary aetiological infectious agent (Walboomers, Jacobs 
et al 1999; Herrero, Castellsague et al 2003). 
The finding of HPV viral DNA integrated in the majority of cellular genomes of 
cervical carcinomas supported the epidemiological evidence that linked this agent to 
cervical cancer. Epidemiological evidences of the most sensitive HPV detection 
methods found that the prevalence of HPV DNA in cervical tumours is over 90% 
(Schiffman, Bauer et al 1993)，which supports the claim that HPV is the causative 
agent (Walboomers, Jacobs et al. 1999; Herrero, Castellsague et al. 2003). The 
presence of HPV DNA in virtually all cases (99.7%) of cervical cancer has also been 
shown (Franco, Rohan et al 1999). 
1.5.2 Number of sexual partners 
The lifetime number of sexual partners has been found to be associated with 
increased risk of^both squamous cell carcinoma and adenocarcinoma of the cervix 
(Green, Berrington de Gonzalez et al 2003b). There has been evidence from 
case-control studies that women with cervical cancer more frequently reported 
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multiple sexual partners than controls. Moreover, the risk appears to increase 
directly with the reported number of sexual partners. The risk associated with 10 or 
more partners has been reported to be nearly three times higher than that associated 
with one or a few partners. The effect of increasing lifetime number of sexual 
partners is found to be stronger for squamous cell carcinoma than for 
adenocarcinoma (Green, Berrington de Gonzalez et al 2003a). For women 
reporting five or more partners compared to those with one partner, the odds ratio for 
squamous cell carcinoma is 1.98 (95% CI: 1.21-3.26). 
In addition, the role of the male in the causation of cervical cancer had also been 
examined by comparing the sexual characteristics of husbands of cervical cancer 
cases with husbands of women free of the disease. In most studies, the husbands of 
cases reported significantly more sexual partners than husbands of controls (Green, 
Berrington de Gonzalez et al. 2003b). 
1.5.3 Age of first sexual intercourse 
Women having sexual intercourse at early age are at higher risk of developing 
cervical cancer than women who have sexual experience later in their life (Thomas, 
Ray et al 2002). Several case-control studies have shown that women with first 
sexual experience before the age of 16 have about twice the risk compared to women 
who start sexual intercourse after the age of 20. The risk of cervical cancer 
associated with earlier age at first intercourse is higher for both squamous cell 
carcinoma and adenocarcinoma, with odds ratio of 2.70 (95% CI: 1.78-4.11) and 
2.01 (95% CI: 1.23-3.30), respectively (Green, Berrington de Gonzalez et al 2003b). 
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1.5.4 Presence of other sexually-transmitted diseases 
History of having sexually-transmitted disease (STD) is associated with an 
increased risk of cervical cancer (Schmauz, Okong et al 1989). Multiple STDs 
have been found to be a risk factor for cervical cancer even after adjustment for HPV 
infection status suggesting that non-HPV STD may act as HPV cofactors. 
Sexually-transmitted pathogens other than HPV and cervical inflammation may 
influence the natural history of HPV infection along the pathways of persistence, 
progression or regression (Castle and Giuliano 2003). 
A case-control study found that, among oncogenic HPV-infected women, 
antibodies to Chlamydia trachomatis were associated with a two-fold increased risk 
of cervical cancer (Smith, Munoz et al 2002b). However, because of poor 
adjustment for HPV, the conclusion for this study was difficult to interpret. 
Another recent multicentric case-control study had provided strong evidence for 
herpes simplex virus type II infection as an HPV cofactor (Smith, Herrero et al 
2002a). Although there is strong evidence that these STD increase the risk of 
cervical cancer, further studies are required to confirm whether infections by these 
STD are surrogates for high-risk behaviour that increases exposure to HPV. 
Also, women with human immunodeficiency virus (HIV) infections are 
significantly at higher risk of cervical cancer than women not infected with HIV 
(Weissenbom, Funke et al. 2003). 
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1.5.5 Cigarette smoking 
Cigarette smoking has long been found associated with an increased risk for 
squamous cell carcinoma of the cervix (Plummer, Herrero et al. 2003). The effect 
of smoking is not diminished by the adjustment for HPV or analysis restricted to 
cases and controls both positive for HPV. There is now sufficient evidence to 
establish a causal association of squamous cell cervical carcinoma with smoking. 
From a pooled analysis of multi-centric case-control studies conducted by the 
International Agency for Research of Cancer (lARC), the risk of cervical cancer for 
ever smoking among HPV-positive women was increased by more than 100% 
(OR=2.17, 95% CI: 1.46-3.22). The risk for cervical neoplasia increased with 
longer duration and intensity of smoking and exposure to environmental tobacco 
smoke. Ex-smokers, women who smoked less than one pack of cigarettes per day, 
and women who smoked one or more packs per day had crude relative risks for CIN 
III or cervical cancer of 2.1 (95% CI: 1.1-3.9)，2.2 (95% CI: 1.2-4.2) and 2.9 (95% 
CI: 1.5-5.6) respectively, compared with the non-smokers (Castle, Wacholder et al. 
2002). 
A prospective study demonstrated that smokers had cervical HPV infections of 
longer duration and lower chance of clearing an oncogenic infection than women 
who had never smoked (Giulian, Sedjo et al. 2002). There is also an association 
between smoking and lower levels of plasma (3-carotene, folate and vitamin C (Smith 
and Hodges 1987; Nierenberg, Stukel et al. 1989; Palan, Romney et al. 1989; 
Heimburger 1992). Moreover, mutagens in cervical mucus are found in smokers 
but not in non-smokers (Holly, Petrakis et al. 1986). The significant association 
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found between the extent of smoking reduction and the reduction in lesion size in an 
intervention study of smoking cessation among women with lower-grade lesions 
further strengthened the possible role of tobacco smoking in HPV carcinogenesis 
(Szarewski, Jarvis et al. 1996). 
1.5.6 Diet 
There is yet no convincing evidence that any dietary factors modify the risk of 
cervical cancer, nor evidence of any probable causal relationship with diet (Glade 
1999). Nevertheless, both case-control and prospective studies demonstrated that 
diets rich in vegetables and fruits, and higher intake of carotenoids, vitamin C and 
vitamin E, found in foods of plant origin, are possibly protective for cervical cancer 
and its pre-cancerous lesion. There are methodological limitations when examining 
the association between cervical cancer risk and dietary intake, and serologic 
measures of nutrient concentrations. Moreover, the presence of other potential 
confounding factors, such as smoking and use of oral contraceptives further 
complicates the interpretation of nutrient studies (Heggie, Wiseman et al. 2003). 
1.5.7 Oral contraceptives 
A recent systematic study pooling results from 28 case-control and cohort 
studies found that increased risk of cervical cancer was associated with the use of 
oral contraceptives (OC) for five years or more among HPV positive women and the 
risk increased with duration of use (Moreno, Bosch et al. 2002; Smith, Green et al 
2003). The odd ratio for use of OC was 1.3 (95% CI: 1.0-1.9) for five to nine years 
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of use, and 2.5 (95% CI: 1.6-3.9) for 10 or more years of use. However, the risk of 
cervical cancer may decrease after use of OC has ceased (Moreno, Bosch et al. 
2002). 
Use of OC has been found to be associated with cervical cancer in many 
epidemiological studies that adjusted for HPV status, suggesting a role of OC use as 
cofactor in HPV carcinogenesis (Castellsague and Munoz 2003). Hormone-related 
mechanisms may promote integration of HPV DNA into the host genome (Kuroki 
1994). 
1.5.8 Parity 
High parity has consistently been found in most case-control studies to be 
associated with both cervical cancer and carcinoma in-situ (Munoz, Franceschi et al 
2002). Major studies limiting the analysis to HPV-positive women also reported an 
increased risk of HGSIL or cervical cancer with an increase in the number of 
pregnancies. In an I ARC pooled analysis, the odds ratio for squamous-cell cervical 
cancer in HPV-positive women with seven or more full-term pregnancies was 3.8 
(95% CI: 2.7-5.5) compared with nulliparous women, and 2.3 (95% CI: 1.6-3.2) 
compared with women who had one or two full-term pregnancies. The risk 
increased linearly with increasing number of pregnancies. However, there was" no 
significant association between risk of adenocarcinoma or adenosquamous 
carcinoma of cervix and number of full-term pregnancies. 
It has been postulated that high parity may increase the risk of cervical cancer 
by maintaining the transformation zone on the ectocervix for many years, facilitating 
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the direct exposure to HPV and, possibly, to other cofactors. Hormonal changes 
induced by pregnancy may also modulate the immune response to HPV and 
influence the risk of persistence or progression. 
1.5.9 Age 
Older women are at higher risk and the peak incidence of cervical cancer in 
Hong Kong is found in the age group of 75-79 (Hospital Authority 2003). 
Although screening for cervical cancer reduces the risk of developing the disease, the 
coverage of screening in women aged 65 years or above is less than 10% in Hong 
Kong (CSD 2003). Women in this age group are less willing to seek medical care 
or go for screening. 
1.5.10 Socio-economic status 
Low socio-economic status is also a risk factor for cervical cancer. Many 
women with low incomes do not have ready access to adequate health care services, 
including cervical smear and treatment of pre-cancerous cervical disease. These 
women may also be under-nourished and under-nutrition may play a role in 
increasing the risk of developing cervical cancer. 
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1.6 Malignant transformation of human 
papillomavirus infection 
Most papillomavirus infections are associated with benign tumours, which 
usually regress spontaneously after a period of months or years (Lee, Collins et al 
1998). However, in some instances benign HPV infections may progress to 
neoplasia and cancer. The best-characterized association of HPVs with cancer is 
that of the high-risk mucosal HPV types such as HPV 16, 18, 31, 45 and 54 with 
cervical squamous cell carcinoma (Schneider 1994). In HPV-associated cervical 
cancers, the viral genome is often integrated into the host chromosome; both E6 and 
E7 ORFs are preserved, and are transcriptionally active in cervical cancer cell lines 
and in HPV-associated neoplasia (Schwarz，Freese et al 1985; Durst, Glitz et al. 
1992) (Figure 1.2). Integration usually occurs in the E1/E2 region and has two 
consequences. The disruption of expression of the E2 transactivator leads to 
up-regulation of the HPV early promoter, and to increased production of the E6 and 
































































































































































































































































The E6 and E7 gene products deregulate the host cell growth cycle by binding 
and inactivating tumour suppressor proteins, cell cyclins, and cyclin-dependent 
kinases (Figure 1.3) (Syrjanen and Syrjanen 1999). The function of the E6 and E7 
gene products during a productive HPV infection is to subvert the cell 
growth-regulatory pathways and to modify the cellular environment in order to 
facilitate viral replication in a cell that is terminally differentiated and has exited the 
cell cycle. Cell growth is regulated largely by two cellular proteins, the tumour 
suppressor protein, p53, and the retinoblastoma gene product, pRB. Unlike in many 
other cancers, the p53 in cervical cancer is usually wild type and is not mutated 
(Thomas, Pirn et al. 1999). The HPV E6 gene product binds to p53 and targets it 
for rapid degradation via a cellular ubiquitin ligase. This degradation has the same 
effect as an inactivating mutation. As a consequence, the normal activities of p53 
which govern Gi arrest, apoptosis, and DNA repair are aborted. Low-risk HPV E6 
proteins do not bind p53 at detectable levels and have no effect on p53 stability 
in-vitro. . 
The HPV E7 gene product binds to the hypophosphorylated form of the RB 
family of proteins. This binding disrupts the complex between pRB and the cellular 
transcription factor E2F-1，resulting in the liberation of E2F-1, which allows the 
transcription of genes whose products are required for the cell to enter the S phase of 
the cell cycle. The E7 gene product can also associate with other mitotically 
interactive cellular proteins such as cyclin E. The outcome is stimulation of cellular 
DNA synthesis and cell proliferation. The E7 protein from low-risk HPV types 
binds pRB with decreased affinity. Moreover, the E5 gene product induces an 
increase in mitogen-activated protein kinase activity, thereby enhancing cellular 
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responses to growth and differentiation factors. This results in continuous 
proliferation and delayed differentiation of the host cell. The El and E2 gene 
products are then synthesized. The E2 gene product is a DNA binding protein 
which blocks transcription of the E6 and E7 genes and permits the El gene product 
to bind to the viral origin of replication located within the LCR. This binding 
initiates replication of the viral genome as extrachromosomal elements in the S phase 
of the cell cycle. Genome copy number is maintained at a constant level in these 
cells, and a low level of transcripts is expressed. The E2-mediated down-regulation 
of E6 and E7 transcription results in the release of the p53 and pRB proteins, and the 
normal differentiation process of the host cell is allowed to continue. Then, a 
putative late promoter activates the capsid genes, LI and L2. Viral particles are 
assembled in the nucleus, and complete virions are released as the cornfield layers of 
the epithelium are shed. The E4 gene product plays a role in the maturation and 
release of papillomavirus particles. The process does not appear to be cytolytic. 
In the replication process, viral DNA becomes established throughout the entire 
thickness of the epithelium but intact virions are found only in the upper layers of the 
tissue. In warts or condylomata, viral replication is associated with proliferation of 
all epidermal layers except the basal layer. This leads to acanthosis, paraderatosis, 
hyperkeratosis, and deepening of rete ridges, creating the typical papillomatous 
cytoarchitecture seen histologically. Some infected cells transform into koilocytes, 
which are large, usually polygonal, squamous cells with a shrunken nucleus inside a 
cytoplasmic vacuole. Excessive proliferation of cells in the basal layer 
accompanied by large number of mitoses, some abnormal, is a feature of malignant 
and premalignant disease. 
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Figure 1.3 Pathogenesis of oncogenic human papillomavirus 
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HPV E6 and E7 genes encode multifunctional proteins that bind primarily to cellular 
p53 and pRB proteins, disrupt their functions, and alter cell cycle regulatory 
pathways, leading to cellular transformation. G1 = gap one phase, G2 = gap two 
phase, M = mitosis phase, S 二 synthesis phase and E2F-1 = E2F transcription factor 
one. (Syrjanen and Syrjanen 1999) 
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1.7 Primary prevention of cervical cancer 一 
vaccine for human papillomavirus 
The recognition of HPV infection as a major cause of cervical cancer has paved 
the way for immunization as one of the strategies for primary prevention. 
1.7.1 Classification of vaccine for human papillomavirus 
Two types of vaccines against the infection with certain types of HPV are being 
developed and are in different phases of clinical trials (Da Silva, Eiben et al 2001; 
Stem, Faulkner et al 2001). Prophylactic vaccines have a potential to elicit strong 
anti-viral response to protect against HPV infection and render the recipient immune 
to HPV. Therapeutic vaccines, based on the induction of cellular immunity directed 
against cells expressing viral proteins, could help women who are infected with HPV. 
The potential use of both vaccines is to induce regression of HPV associated lesions, 
eliminate the residual cancer, as well as to prevent infection (Galloway 1998). 
Some criteria must be met so that HPV vaccine is developed into a safe and 
effective means of preventing and controlling diseases (Greenwood 2005). At first, 
it must be effective against the common high-risk types of HPV associated with 
cervical cancer. Secondly, it must offer a long-lasting protection against HPV and 
preferably without booster shots. And thirdly, economic production cost is also a 
main factor in determining wide-spread use. Preliminary trials of the vaccines have 
shown some success. 
•S.. 
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1.7.2 Human papillomavirus vaccination combined with 
human papillomavirus screening 
Although prevention of infection with HPV 16 by prophylactic vaccine has been 
established (Koutsky, Ault et al 2002)，the efficacy of immunizing HPV negative 
women against this vims needs further research before screening programme using 
HPV testing as screening tools could be implemented. 
Human papillomavirus vaccination in combination with HPV screening test can 
be a cost-effective intervention. However, it depends on maintaining effectiveness 
during the ages of peak oncogenic HPV incidence. Identifying the optimal age for 
vaccination should be a research priority (Kulasingam and Myers 2003). The 
advantage of an HPV vaccine is not only to prevent HPV infection, but also to 
prevent the causative agent from residing in the genital tract where it can infect new 
sexual partners (Crum 2002). 
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1.8 Secondary prevention of cervical cancer 
Secondary prevention aims at lowering the occurrence of the later and more 
severe stages of the disease, often by identifying the disease at an early and curable 
stage, as in screening, therefore reducing the prevalence of the disease through 
treatment (Rogers, McEwen et al. 2002). 
1.8.1 Cytology screening 
Cervical smear (Pap smear) is a simple test that can detect early abnormal 
changes in the cells of the cervix. Early detection followed by appropriate 
treatment can achieve a very high cure and survival rate. Women with pre-invasive 
lesions have a five-year survival rate of nearly 100% after treatment. The results of 
meta-analysis of studies suggest that the sensitivity of cytological screening has a 
wide range of 30-87%. Sensitivity of cytological screening for detection of HGSIL 
is in the range of 70-80%. The specificity of a cervical smear has been reported to 
be as high as 90%. Factors that limit this test sensitivity include small size of the 
lesion, inaccessible location of the lesion, the lesion not being sampled or the 
presence of inflammation and/or blood obscuring cell visualization (Saslow, 
Runbwicz et al. 2002). 
The International Agency for Research on Cancer (lARC) conducted a 
collaborative study of screening programmes in eight countries which showed that 
little was gained by screening every year compared to screening every two or three 
years. The percentage reduction in cumulative incidence among women aged 35-64 
years who had a second negative smear at the age of 35 was 93.5% when the interval 
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between cervical smears was one year, 92.5% at two years interval, 90.8% at three 
years interval and 83.6% at five years interval (lARC 1986). 
Also, a cohort study in Denmark found that women with two to four previous 
normal cytology results had a negligible risk of developing cancer within two years 
(Bigaard, Hariri et al. 2000). Repeat screening at regular intervals compensates for 
the limitations in the sensitivity of the technique. While more frequent screening 
increases sensitivity, it also increases stress and costs in patients (Saslow, Runowicz 
et al 2002). 
1.8.2 Detection of human papillomavirus 
Persistent detection of high-risk HPV types is a strong predictor for the 
development of cervical cancer. Compared with cytology, HPV DNA testing is 
significantly more sensitive, but less specific in the detection of CIN III or higher 
lesions. For HGSIL, the sensitivity and specificity of HPV test is around 90% and 
51% respectively (Ratnam, Franco et al. 2000). 
HPV DNA testing has been found to be more cost effective than other 
management strategies including repeated cervical cytology or immediate 
colposcopy for women diagnosed as having atypical squamous cells of undetermined 
significance (ASCUS). Since around half of ASCUS has high-risk HPV, HPV 
detection in triaging women with ASCUS is an alternative to repeat cytology at six 
months for deciding whether colposcopy referral is needed. On the other hand, 
HPV detection has limited advantage in triaging patients with LGSIL for colposcopy 
because over 80% of LGSIL has high-risk HPVs (Desai and Cubic 2005). 
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A positive HPV DNA test result is not an absolute indicator that high-grade 
lesions exist or will develop (Franceschi and Clifford 2005b). The prognostic value 
of a positive test result, especially in the absence of a cytological abnormality, has 
not been fully validated in prospective studies. Harms of HPV testing may include 
anxiety or stigmatization among infected women and impact on relationships with 
sexual partners. 
The reported positive predictive value of an HPV test for HGSIL and carcinoma 
is less than 10% (Kulasingam, Hughes et al. 2002). The suitability of HPV typing 
for routine screening in asymptomatic women is limited by its poor predictive value 
and uncertain natural history. Moreover, due to the absence of an effective 
treatment, there is lack of evidence that screening affects clinical outcomes 
(Bollmann, Bankfalvi et al 2005). 
Although there is evidence to suggest that HPV testing in conjunction with 
cytology may improve the screening efficacy of cytology alone, more evidence is 
required to confirm whether the benefit outweighs the high cost of HPV testing (Jin, 
Zanotti et al. 2005). 
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1.9 Human papillomavirus and cervical cancer 
1.9.1 Risk association between cervical cancer and human 
papillomavirus infection 
There are over 200 distinct types of HPV identified and approximately 40 of 
them are known to infect the human genital tract. Studies have shown that up to 
70% of all sexually active women have been infected by HPVs, although only 5% 
will go on to develop cervical cancer (Bosch, Manos et al. 1995). Epidemiological 
studies suggest that 15 HPV genotypes, called oncogenic or high-risk types, are 
significantly associated with progression to cervical cancer. The high oncogenic 
risk group includes HPV 16, 18，31，33，35, 39, 45，51, 52，56，58，59, 68，73 and 82 
(Munoz, Bosch et al. 2003). 
Based on a recent study, an estimate of the pooled odds ratio for cervical cancer 
associated with the presence of any HPV was 158.2 (95% CI: 113.4 to 220.6) (Munoz, 
Bosch et al 2003). The corresponding risk estimates for HPV 16 and HPV 18 were 
434.5 (95% CI: 278.2 to 678.7) and 258.1 (95% CI: 138.1 to 445.8) respectively. 
1.9.2 World-wide prevalence of human papillomavirus types 
in cervical cancer 
In a meta-analysis of world-wide prevalence of HPV types, more than 75% of 
cervical cancer cases were associated with HPV 16 (60%) or HPV 18 (19%) 
infection (Figure 1.4). However, the prevalence of specific HPV types varies with 
geographical region (Figure 1.5). In Asia, HPV 58 and HPV 52 are more prevalent 
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and are found in nearly 10% of all cervical cancer cases, compared to less than 1% in 
North America and Australia, or 3.4% world-wide (Clifford, Smith et al. 2003b). 
1.9.3 Human papillomavirus prevalence in China and Hong 
Kong 
On the basis of data from all regions of China, 132,300 new cases of cervical 
cancer were reported in 1990，indicating an overall incidence rate of 27 per 100,000 
women (Parkin, Pisani et al. 1999). In Hong Kong, the overall incidence rate is 
lower than mainland China (10.1 per 100 000 women) (Department of Health 2003b). 
Although the overall incidence rate of cervical cancer in Hong Kong and mainland 
China is different, HPV genotype prevalence and distribution are similar in both 
regions. Previous studies have shown HPV 16 and 18 are the two most common 
types in world-wide and follwed by HPV 45,31 , 33，58 and 52 (Clifford, Smith et al. 
2003b). However, the prevalence rate of HPV 52 and 58 are higher than HPV 31， 
33 and 45 in Hong Kong (Figure 1.6) (Chan, Lau et al. 1996). This unusual high 
prevalence rate of HPV 52 and 58 is also found in Japan, South Korea and Taiwan 
(Pao, Kao et al. 1993; Maehama, Asato et al. 2002; Shin, Lee et al. 2003), but less 
prevalent was found in South East Asia, including India, Indonesia, Philippines and 
Thailand (Takami, Kondoh et al. 1991; Chichareon, Herrero et al. 1998; Ngelangel, 
Munoz et al 1998; Rajkumar, Franceschi et al. 2003). 
A study by Munoz and associates (2004) shows that a vaccine including HPV 
16 and HPV 18 could potentially prevent 71% of cervical cancers worldwide, and 
73.5% in Asia, but this study did not include the data from China and the author 
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point out that the power of the vaccine may be over-estimated. Therefore, when 
designing a HPV vaccine for Asian population, the priority of vaccine candidate may 
affect the efficiency of vaccine. 
V. 
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Figure 1.4 World-wide prevalence of HPV genotypes in cervical cancer 
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Figure 1.6 Prevalence of HPV types found in cervical cancer in Hong Kong 
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chapter Two 
Materials and Methods 
49 
2.1 Ethics approval 
All studies were approved by the local institutional ethics committee. Clinical 
materials were collected under a written informed consent. Human experimentation 
guidelines of the local institute were followed in conducting of these studies. 
2.2 Sample management 
2.2.1 Sample collection 
Cervical samples of paraffin-embedded biopsy, fresh frozen biopsy and cervical 
exfoliated cells (cervical scrapes) were collected for this project. All samples were 
collected at the Prince of Wales Hospital, Shatin, Hong Kong from 2000 to 2005. 
For formalin-fixed and paraffin-embedded biopsy, four to five pieces of 4 mm thick 
tissue section of each sample were collected. Fresh biopsies were collected in viral 
transporting medium taken at the time of operation. Cervical exfoliated cells were 
collected by Cytobrush® (Hardwood Products Company, USA) and immersed in 10 
mL PBS during cytology screening. 
2.2.2 Sample storage and labelling 
All samples were labelled with an unique laboratory number so that the 
researcher is blind to sample's information and diagnosis. Also, all samples and the 
extracted DNA were stored separately at -70°C freezers until use to avoid 
contamination. 
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2.3 Total DNA extraction 
Total DNA was extracted using two extraction methods — physical and chemical 
extractions. The chemical method was used for all biopsies samples. Physical 
extraction was performed as the primary extraction of choice for cervical scrapes 
samples. Cervical scrapes samples with negative-P-globin PCR result were 
re-extracted again using chemical extraction. 
2.3 DNA extraction 
2.3.1 Physical extraction - heating 
Total DNA of cervical scrape samples were heated at 95°C for 15 min and 
centrifuged to pellet the cell debris. This method disrupts the cell membrane of the 
cervical exfoliated cells to release DNA but this method cannot remove inhibitors. 
2.3.2 Chemical extraction 一 Qiagen kit extraction 
Chemical extraction was performed by using the QIAmp DNA mini kit 
(QIAGEN, Germany). Following the manufacturer's protocol, 200 pL lysis buffer, 
AL and proteinase K were added to 200 pL sample followed by incubation at 70°C 
for 10 min for cervical scrape samples or overnight for biopsy samples. Absolute 
ethanol (200 pL) was then added and the mixture was applied to the spin column for 
centrifugation. Buffer AWl (500 \aL) was added and the spin column was 
centrifuged at 8,000 rpm for 1 min, followed by the addition of buffer AW2 (500 |jL) 
to the spin column. This was then centrifuged at 13,000 rpm for 3 min. After 
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each washing step, the filtrate was discarded. Finally, elution buffer AE (200 pL) 
was added to the spin column. The spin column was incubated at room temperature 
for 1 min, and then centrifuged at 8,000 rpm for 1 min. The spin column was 
discarded and extracted DNA was collected in a micro-centrifuge tube for later use in 
PCR. DNA extraction and PCR were performed in separate rooms to avoid 
cross-contamination. 
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2.4 Polymerase chain reaction 
2.4.1 Controls for polymerase chain reaction 
Lysates from CaSki cells (HPV 16 positive) (ATCC, USA), HeLa cells (HPV 18 
positive) (ATCC, USA), or human leukocytes (containing human housekeeping gene 
p-globin) were used as positive controls. Negative control using distilled water was 
added following every fifth specimen to check for PCR contamination as described 
elsewhere (Coutlee, Mayrand et al. 1997). 
2.4.2 Beta-globin polymerase chain reaction 
To check for the integrity and adequancy of the DNA in samples, the human 
housekeeping gene (3-globin，was targeted for PCR (Coutlee, Gravitt et al. 1999). 
Three sets of P-globin primers with different PCR product size were designed 
accordingly to monitor the product length. The primer sequences are showed in 
Table 2.1. 
The 5 0 | L I L PCR reaction mixture contained Tris-HCl (pH 8 . 7 ) , K C L , ( N H 4 ) 2 S 0 4 ， 
1.5 mM MgCb, one unit of HotStarr叫 DNA polymerase (QIAGEN, Germany), 0.2 
mM of each dNTP (Amersham Biosciences, UK), 0.25 |iM of each primer (Proligo, 
Singapore). Five microlitre of extracted DNA was used as template. The PCR 
cycling conditions were initial denaturation and enzyme activation at 95°C for 15 
minutes, followed by 40 cycles of 1 min denaturation at 94°C, 1 min annealing at 
57/58°C and 1 min extension at 72°C. An additional extension step was carried out 
53 
_ 
• at 72°C for 8 min. 
Ep'' 
I； . _ . . 
^ • • • 
I； 
I: 
I ; 3 
Iv •• - r . . 
b • - •‘ • ... . . . . � . • 









B P , 
_ 




Table 2.1 Primer sequences of beta-globin polymerase chain reaction 
Beta-globin PCR primers 
PC04/GH20 
expected product size: 268 bp forward-5 ‘CAACTTCATCCACGTTCACC-3 ‘ 
Tm = 57�C reverse-5 ‘ GAAGAGCC AAGGAC AGGTAC-3 ‘ 
BGP1Z2 J … . f o r w a r d -5' ATGGTGC ACCTGACTCCTGAGG-3 ‘ 
expected product size: 355 bp reverse -5'GCCATCACTAAAGGCACCGACG-3' 
Tm = 58°C 
PC03/07 forward -5'ACACAACTGTGTTCACTAGC-3' 
expected product size: 509 bp reverse -5'GAAAACATCAAGGGTCCCAT-3' 
Tm = 58�C 
Three beta-globin primer sets were used to check the adequancy of extracted DNA; 
PC04/GH20, BGP 1/2 and PC03/07. Expected product sizes are 268 bp, 355 bp and 
509 bp, respectively. (Coutlee, Gravitt et al. 1999) 
� 
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2.4.3 HPV 52-specific human papillomavirus polymerase 
chain reaction 
Two primers HPV52-E6-forward (nt42-60, 
5，- ACGGTC AGACCGA AACCGG-3，）and HPV52-E7-reverse (nt1062-1014, 
5'-CCGGGCTGCCTCATGTTCT-3') were designed from the published HPV 52 
complete genome sequence (GenBank, accession number: NC—001592) (Shimoda, 
Lorincz et al. 1988) for sequence variation analysis. This primer set amplified a 
1020-bp fragment which contains the complete 447-bp E6 ORF and 300-bp E7 ORF. 
PGR were carried out using 5 jjL of extracted DNA in a 50 pL reaction volume that 
contained Tris-HCl (pH 8.7), KCl, (NH4)2S04，2.5 U of HotStarra? DNA polymerase 
(QIAGEN, Germany), 0.04 mM of each dNTP (Amersham Biosciences, UK) and 
0.25 |liM of each primer. Cycling conditions of PGR were initial denaturation at 
95°C and enzyme activation for 15 minutes, followed by 40 cycles of 1 min 
denaturation at 94°C, 1 min annealing at 58°C and 1.5 min extension at 72°C. An 
additional extension step was carried out at 72�C for 8 min. 
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2.4.4 Consensus human papillomavirus L1 open-reading 
frame polymerase chain reaction 
Three sets of consensus HPV Ll-ORF PCRs (GP5+/6+, MY09/11 and 
PGMY09/11) were performed in this project. All of the three methods were used in 
study I，PGMY09/11 was used in study II for HPV DNA screening. 
2.4.4.1 GP5+/6+ polymerase chain reaction 
The GP5+/6+ primer set consists of two general primers and a wide range of 
HPV types can be detected using a lowered annealing temperature during PGR (de 
Roda Husman, Walboomers et al. 1995). The expected product size was 165 bp. 
This primer set targets the conserved LI HPV region and detects a wide spectrum of 
HPV types (Table 2.2). The sequence of the forward primer (GP5+) was 
5'-TTTGTTACTGTGGTAGATACTAC-3‘ and the sequence of the reverse primer 
(GP6+) was 5'-GAAAACATCAAGGGTCCCAT-3‘. The 50 ^L PGR reaction 
mixture contained Tris-HCl (pH 8.7), KCl, (NH4)2S04，1.5 mM MgClz, 1 U of 
HotStarr^^ DNA polymerase (QIAGEN, Germany), 0.2 mM of each dNTP 
(Amersham Biosciences, UK), 0.25 |iM of each primer (Proligo, Singapore) and 5 
|LiL‘of extracted DNA. The PGR cycling conditions were initial denaturation and 
enzyme activation at 95°C for 15 min, followed by 40 cycles of 1 min denaturation at 
94°C, 1 min annealing at 45°C and 1 min extension at 72�C. An additional PGR 
extension step was carried out at 72°C for 8 min. 
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Table 2.2 Alignment of GP5+/6+ primer sequences with 23 HPV types 
Sequence name and HPV type Sequence (5 ' -3 ' ) 
GP5+ n r GIT ACT GTG GTA GAT ACT AC 
HPV6B C . . 
HPV 11 C . . 
HPV 13 A ..T 
HPV 16 T ..T 
HPV 18 C •• 
HPV 30 T ..G ..C ..C . . 
HPV 31 C . . 
HPV 32 . . . C.A T ..G 
HPV 33 C . . 
HPV 34 . . . T.A ……T 
HPV 35 A ..T A . . 
HPV 39 . . . C T ..G ..C 
HPV40 A ..T C ..C . . 
HPV42 . . . T.A T 
HPV 45 A ..G ..C 
HPV 51 . . . A.. . .C TGT . .T 
HPV 52 ……C ..A ..T ..G ……C .. 
HPV 53 ……A ……T ..G ……C .. 
HPV 56 A 
HPV 58 C . . 
HPV 61 ……A ..C ..T ..G ……C .. 
HPV 66 T ..G 
GP6+ GAA AAA TAA ACT GTA AAT CAT ATT C 
HPV6B T C . . 
HPV 11 A . C . . 
HPV 13 T A . . . . 
HPV 16 
HPV 18 C 
HPV 30 … . C . C . . . . T •. 
HPV 31 . . . -T T A . . . . 
HPV 32 … . T T 
HPV 33 C G.. ..A . . . . 
HPV 34 . . . .C. C C. GG C . . 
HPV 35 
HPV 39 � . . . .T T C . . 
HPV 40 C A . C . . 
HPV 42 … . T T. .C. C 
HPV 45 " 
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HPV 51 T. .C. .T C . . 
HPV 52 T A . . . . 
HPV 53 . . . .C. C.. .T T 
HPV 56 C.. .T T 
HPV 58 C G 
HPV 61 T. .C A . C . . 
• • • • C • C • • • • • • • • CJT • • • • • • • • 
The primer sequences are in boldface type with the corresponding HPV sequence 
alignments underneath. Nucleotide homology is indicated with a period, and 
mismatches are indicated with the nucleotide change in the corresponding sequence, 
(de Roda Husman, Walboomers et al 1995) 
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2.4.4.2 MY09/11 polymerase chain reaction 
A pair of degenerate MY09/11 consensus primers was used to amplify a 450 bp 
fragment from the conserved LI ORF of HPVs (Chen and Mounts 1990). The 
MY09/11 primer set was synthesized with several degenerate nucleotides in each 
primer and was thus a mixture of primers pool, capable of amplifying a wide 
spectrum of HPV types (Table 2.3). The 50 }iL PCR reaction mixture contained 
Tris-HCl (pH 8.7), KCl, (NH4)2S04, 1.5 mM MgClz, 1 U of HotStarJa^ DNA 
polymerase (QIAGEN，Germany), 0.2 mM of each dNTP (Amersham Biosciences, 
UK), 5 pL of extracted DNA and 0.25 i^M of each primer (Proligo, Singapore), 
forward primer MYll: 5'-GCMCAGGGWCATAAYAATGG-3‘； reverse primer 
MY09: 5'-CGTCCMARRGGAWACTGATC-3‘ (M =A or C; R =A or G; W =A or T; 
Y =C or T). The PCR cycling conditions were initial denaturation and enzyme 
activation at 95°C for 15 min，followed by 40 cycles of 1 min denaturation at 94�C, 1 
min annealing at 55°C and 1 min extension at 72°C. An additional extension step 
was carried out at 72°C for 8 min. 
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Table 2.3 Alignment of MY09/11 primer sequences with 18 HPV types 
Sequence name and HPV type Sequence (5 一 -3 ') 
MY09 CGT CCM ARR GGA WAC TGA TC 
HPV 6 
HPV 1 1 
HPV 1 6 T 
HPV 1 8 T 
HPV 2 6 . . C . . T . . T ……T …… 
HPV 3 1 - . A T 
HPV 3 3 
HPV 3 5 . . G C 
HPV 3 9 G . . T 
HPV 4 0 ……T . . T ……T …… • 
HPV 4 2 .TA . . T T …… 
HPV 4 5 - . A T 
HPV 5 2 .TA . . T 
HPV 5 3 .TG 
HPV 5 5 .TA T …… 
HPV 5 6 .TA ……T ……T …… 
HPV 5 8 
HPV 5 9 
MYll GCM CAG GGW CAT MY AAT GG 
HPV 6 
HPV 1 1 . . T 
HPV 1 6 C . . C 
HPV 1 8 
HPV 2 6 
HPV 3 1 - - T C 
HPV 3 3 A 
HPV 3 5 A . . C 
HPV 3 9 C . . C 
HPV 4 0 C •• 
HPV 4 2 A C 
HPV 4 5 C 
HPV 5 2 - - G C . . C 
HPV 5 3 
HPV 5 5 . - G C . . C 
HPV 5 6 - A . . C 
HPV 5 8 A 
HPV 5 9 . . T TTA 
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The primer sequences are in boldface type with the corresponding HPV sequence 
alignments underneath. Nucleotide homology is indicated with a period, and 
mismatches are indicated with the nucleotide change in the corresponding sequence. 
The degenerate base code is as follows: M = A or C, W = A or T, Y = C or T, and R = 
A or G. (Chen and Mounts 1990) ’ ’ 
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2.4.4.3 PGMY09/11 polymerase chain reaction 
PGMY09/11 primer set contains a pool of 17 primers that target a 450 bp 
fragment of the HPV LI conserved region (the primer sequences are shown in Table 
2.4). Primer set PGMY09/11 was modified from MY09/11 by Coutlee and 
co-workers in 2002 to eliminate the degeneracies and to improve the sensitivity, 
specificity, and reproducibility of LI consensus PCR (Coutlee, Gravitt et al 2002). 
This primer pool accommodates the efficient amplification of the following 
HPV genotypes to at least a sensitivity of 10 genomes per PCR: HPV 6，11, 16，18, 
26，31，33，35, 40，45, 51，52, 56, and 59. Several other HPV genotypes, including 
HPV 39, 42，53，54, 55, 58, 61, 62，64，66，67，68，69，70，71，72, 73, IS39, CP8304, 
CP6108, MM4, MM7, and MM8 are also amplified better with PGM09/11 than with 
MY09/11 (Coutlee, Gravitt et al. 2002). 
The reaction mixture of 50 ^L contains lOmM Tris/HCl, pH 8.3，50 mM KCl, 
2.5 mM MgCb, 0.2 mM of each dNTP (Amersham Biosciences, UK), 0.25 |iM of 
each primer (Proligo, Singapore), 1.5 U of AmpHrag Gold (Applied Biosystems, 
Foster City, CA，USA), and 5 i^L of DNA template. The PCR conditions were 
initial denaturation and enzyme activation at 95°C for 9 min, followed by 40 cycles 
of 1 min denaturation at 94°C, 1 min annealing at 55°C and 1 min extension at 72�C. 
An additional extension step was carried out at 72°C for 8 min. 
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Table 2.4 Primer sequences of PGMY09/11 polymerase chain reaction 
PGMY09/11 PCR primer sequences 
Forward primer 
PGMYl 1 -A 5,-GCA CAG GGA CAT AAC AAT GG-3’ 
PGMYll-B 5'-GCG CAG GGC CAC AAT AAT GG-3' 
PGMYl 1 -C 5'-GCA CAG GGA CAT AAT AAT GG-3’ 
PGMYl 1-D 5，-GCC CAG GGC CAC AAC AAT GG-3' 
PGMYll-E 5'-GCT CAG GGT TTAAAC AAT GG-3' 
Reverse primer 
PGMY09-F 5'-CGT CCC AAA GGA AAC TGATC-3' 
PGMY09-G 5 '-CGA CCT AAA GGA AAC TGATC-3’ 
PGMY09-H 5'-CGT CCA AAA GGA AAC TGATC-3' 
PGMY09-I 5'-GCC AAG GGG AAA CTG ATC-3’ 
PGMY09-J 5'-CGT CCC AAA GGA TAG TGA TC-3' 
PGMY09-K 5'-CGT CCA AGG GGA TAC TGA TC-3’ 
PGMY09-L 5'-CGA CCT AAA GGG AAT TGA TC-3' 
PGMY09-M 5 ’-CGA CCT AGT GGA AAT TGA TC-3 ’ 
PGMY09-N 5'-CGACCAAGG GGA TAT TGA TC-3 ’ 
PGMY09-P 5，-GCC CAA CGG AAA CTG ATC-3' 
PGMY09-Q 5，-CGA CCC AAG GGA AAC TGG TC-3' 
PGMY09-R 5，-CGT CCT AAA GGA AAC TGG TC-3’ 
All primers are 20 bp in length except for PGMY09-I and PGMY09-P which are 18 
bp in length. The first two 5' bases of these two primers were deleted to reduce the 




2.5 Genotyping of human papillomavirus 
2.5.1 Restriction fragment length polymorphism 
Restriction fragment length polymorphism (RFLP) was carried out using the 
restriction endonucleases Ddel and Rsal (Roche, Germany). Five microliters of 
each positive-MY09/ll PCR product were digested with 0.3 mL of Ddel and Rsal 
(0.1 U/pL) separately in a 10 pL reaction mixture (Bernard, Chan et al. 1994b). For 
each enzyme digestion, amplified CaSki DNA and HeLa DNA were used as positive 
controls to check for enzyme activity. 
The mixture was incubated at 37°C overnight with subsequent heating at 95°C 
for 5 min to terminate the digestion. Electrophoresis was carried out using a 3% 
superfine agarose gel (SFR™ Agarose, AMRESCO, USA) at 100 V for three hours. 
Five microgram of 25-bp DNA Ladder (Invitrogen^^ life technologies, USA) was 
used as DNA marker to identify the size of the restriction fragments. The gel was 
stained with ethidium bromide for 30 min, followed by destaining using tap water for 
15 min. RFLP patterns were visualized under UV light. HPV types were 
identified by comparison with results published in previous literature (Bernard, Chan 
et dl 1994b) (Table 2.5). 
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Table 2.5 Predicted restriction fragment length patterns for 38 genital HPVs 
digested with Rsa I and Dde I of MY09/11 PCR products. 
Undigested Fragment length(s) of PCR products 
HPV genotype …口） 滅 digested (bp) Ddel digested (bp) 
^ 449 62,72, 149，161 67,382 
11 449 26,72, 135,216 2,447 
13 455 72，73,135,175 62,67,326 
16 452 70，72，310 452 
18 455 38,72,85, 125, 135 23,432 
26 455 18,72,365 455 
31 452 2,167,283 72,380 
32 449 72, 161,216 21, 108,320 
33 449 39,72，102,236 52,77,320 
34 458 15，96, 161，186 8,88, 151,211 
35 452 42，72, 161, 177 23, 135,294 
39 455 72, 123，260 131,324 
40 455 90,365 158,297 
42 449 72, 135,242 108，341 
44 455 72，161，222 46, 112,297 
45 455 45,72,338 131,324 
51 452 72,380 90,362 
52 449 449 92,357 
53 449 449 85, 158,206 
54 452 72， 117， 125， 138 452 
55 455 57,72, 161, 165 46,85, 101,111, 112 
56 449 18,49,72,310 142,307 
57 449 449 46,50, 142,211 
58 452 32，111, 306 101,348 
59 455 452 452 
61 449 18,72,180,185 455 
66 455 449 158,291 
68 455 38,72，85，260 455 
70 455 29,72, 123,231 455 
71 452 72,380 132,320 
� 7 3 458 96,161,201 215,243 
81 452 452 452 
82 455 72,383 167,288 
83 452 72，380 452 
84 452 142,310 90,142,220 
89 452 72,380 54,152,246 
LVXIOO 455 18，72，365 155,297 
LVX160 455 29，72，123，231 455 
Fragment lengths produced from digestion of MY09/11 PCR products with 
restriction endonucleases Ddel and Rsal, as predicted from published HPV 
sequences. (Bernard, Chan et al. 1994b) 
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2.5.2 Reverse line-blot hybridization 
Reverse line-blot hybridization is a PCR-based HPV genotyping method which 
can simultaneously identify multiple HPV types. For each specimen, 10 |il of 
extracted DNA was subjected to PGR amplification using the pre-market Roche HPV 
genotyping kit (Roche Molecular Systems, Inc., Alameda, CA, USA). This method 
(Gravitt, Peyton et al. 1998; Gravitt, Peyton et al. 2000) utilized biotinylated primers 
(PGMY09/11) that amplify a 450 bp fragment of the LI open-reading frame of a 
broad spectrum of genital HPV genotypes. A control set of biotinylated primers 
(GH20/PC04) simultaneously amplified a 268 bp fragment of the human (3-globin 
gene in each reaction. Resulting PCR products were then denatured and hybridized 
to separate HPV genotyping strips that contains an immobilized array of 27 HPV 
probes (old version) or 37 HPV probes (new version). Hybridized PCR products 
were detected using a streptavidin-horseradish peroxidase detection system. Each 
genotyping strip contains P-globin probes at two different concentrations to act as 
internal controls for the interpretation of PCR inhibition and DNA adequancy. 
Each sample of DNA was amplified using the HPV LI consensus primers 
PGMY09/11 and P-globin primer PC04/GH20. The amplification mixture 
contained 6 mmol/L MgCb, IX PCR buffer II (Amplirag Gold; Roche Molecular 
Diagnostics), 7.5 U of Gold Tag DNA polymerase (Amplira^ Gold; Roche 
Molecular Diagnostics), 200 ijmol/L dNTPs, 50 pmol of PGMY09 and PGMYll 
primers, 10 pmol of PC04 and GH20 primers, and 5 |LIL of template DNA, in a final 
volume of 50 |nL. -The DNA was amplified using the following program: 9 min at 
95�C; 30 s at 95°C, 60s at 55°C and 60s at 72°C, for 40 cycles; and 10 min at 72�C. 
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Forty microliters of PGR products was then mixed with 40 [iL amplicor denaturation 
solution. Seventy microliters of denatured PCR product was added to each well of 
an amplicor typing tray containing 3 mL of preheated hybridization solution (4X 
saline sodium phosphate EDTA [SSPE] and 0.5% SDS) and a probe-labelled 
hybridization strip. The tray was incubated for 30 min at 53°C and then washed 
with 3 mL washing solution (IX SSPE and 0.1% SDS) for 15 min at 53�C and again 
at room temperature. After washing, 3 mL of amplicor streptavidin-horseradish 
peroxidase conjugate was added, and the tray was incubated for 30 min at room 
temperature. The tray was washed twice with 3 mL of washing solution for 15 min 
at room temperature then with 3 mL of citrate buffer. The substrate was prepared 
by mixing 0.01% H2O2 and 0.1% ProClin in a 0.1 mol/L citrate solution with 0.1% 
tetramethylbenzidine in dimethylformamide. Three millilitres of substrate was 
added to each well, and the strips were incubated for 5 min at room temperature and 
then rinsed with distilled water. The results were recorded within 30 min. 
Samples displaying hybridization to only the high concentration P-globin probe 
(indicative of either PCR inhibition or extremely low DNA) were not included into 
final analysis. A negative control was included with each batch of specimens tested 
and was consistently negative. 
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2.6 Sequencing 
2.6.1 Sequencing for HPV genotyping 
Sequencing by ABI 3700 system was used for HPV genotyping in study I. 
Cycle sequencing was performed by 3730x1 DNA sequencer (Applied Biosystem, 
Foster City, CA) using BigDye™ terminator kit (Applied Biosystem, Foster City, 
USA) according to the manufacturer's protocol. Each 10 pL matrix for cycle 
sequencing contained 3.2 |iiM primers (GP5+/6+ or MY09/11), 10-40 ng PCR 
product, 2 |iL reaction premix and 1 |LIL BigDye sequencing buffer. The sequencing 
condition was an initial denaturation step at 96°C for 1 min, followed by 25 cycles at 
96°C for 10 seconds, 50°C for 5 seconds and 60°C for 4 min. After cycle 
sequencing, DNA purification was carried out by ethanol precipitation. The DNA 
sequence products were precipitated using 5 |uL 125 mM EDTA in 100% ethanol, 
after centrifugation of 4000 rpm at 4°C for 30 min, the products were washed by 60 
|LIL 70% ethanol and centrifuged at 4000 rpm for 4 min to remove residue salts and 
dNTPs. Then, samples were resuspended in 10 pL Hi-Di formamide (Applied 
Biosystems, Foster City, CA). 
2.6.2 Sequencing of HPV 52 E6 and E7 genes 
MegaBACfiTM 1000 system was used for sequence variation analysis of HPV 52 
E6 and E7 genes in study III. MegaBACE^'^ 1000 system (Amersham Biosciences, 
USA) was performed by using DYEnamic^^ ET Dye Terminator Kits (Amersham 
Biosciences, USA). This system is a fluorescence based capillary electrophoresis 
system that simultaneously analyses up to 384 DNA samples Each 10 \aL matrix for 
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cycle sequencing contained 5 (iM primers (HPV 52-E6: nt46-63, 
5 '-ACGGTCAGACCGAAACCGG-3 ‘ or HPV 52-E7: ntl046-1064, 
5 '-CCGGGCTGCCTCATGTTCT-3'), 40-60 ng PCR product and 3 ^L MegaBACE 
Long Red Matrix (LPA). The sequencing condition was an initial denaturation step 
at 94�C for 4 min, followed by 35 cycles at 94°C for 15 sec, 60°C for 15 sec and 
72°C for 20 sec. After cycle sequencing, DNA purification was carried out by 
ethanol precipitation. DNA product was precipitated using 1 i^L 7.5 M ammonium 
acetate in 30 ^L 95% ethanol, after centrifugation of 4000 rpm at 4°C for 30 min, 
DNA product was washed by 100 i^L 70% ethanol and centrifuged at 4000 rpm for 4 
min to remove residue salts and dNTPs. Then, samples were resuspended in 10 laL 
loading buffer. 
2.7 Statistical analysis 
The correlation between two parameters was evaluated by Chi-Square test. 
However, if the expected value was less than five, Fisher's exact test was chosen. 
Obtained P-values less than 0.05 (two-sided) were considered statistically significant. 
All statistical calculations were carried out using the software SPSS 10.0 (SPSS Inc., 
Chicago, IL, U.S.A.). 
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3.1 Objective 
This study was to evaluate and compare three DNA detection methods for the 
detection of HPV prevalence. 
3.2 Study plan 
Cervical cancer specimens including fresh frozen and paraffin-embedded 
biopsies were collected in the Department of Obstetrics and Gynaecology, Prince of 
Wales Hospital, Hong Kong between 2001 and 2004. Histopathological diagnosis 
of all samples was done by the Department of Anatomical and Cellular Pathology in 
the same hospital. Total DNA was extracted by QIAmp DNA mini kit (QIAGEN, 
Germany), DNA integrity and adequancy were assessed by P-globin PCRs 
(PC04/GH20, BGPl/2 and PC03/07) to avoid false-negative results (Chan, Chan et 
al. 2001). Human papillomavirus detection and typing was accomplished by three 
different methods in parallel. In the first method, HPV DNA was amplified by the 
GP5+/6+ primers (de Roda Husman, Walboomers et al. 1995) and HPV type 
identified by cycle sequencing of PCR amplicons by ABI 3700 cycle sequencing 
(Applied Biosystems, Foster City, CA). In the second method, the MY09/11 
primers were used for PCR (Ting and Manos 1990)，and HPV type was identified by 
RFLR Ambiguous RFLPs were resolved by cycle sequencing (using ABI 3700 
cycle sequencer, Applied Biosystem, Foster City, CA) of PCR amplicons. The third 
method was based on a pre-market Roche HPV genotyping kit (Roche Molecular 
Systems, Inc., California). This kit uses the biotinylated PGMY09/11 primers 
followed by hybridization with 27 HPVs type-specific probes immobilised on a strip 
for the detection of HPV types (Coutlee, Gravitt et al. 2002) (Figure 3.1). Details 
of each method is described in Chapter Two: Materials and Methods. 
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Figure 3.1 Study plan of study I - Comparison of three HPV DNA detection 
methods 
Cervical cancer samples 
Fresh frozen biopsies 
Paraffin-embedded biopsies 
< Histopathological results 
Total DNA extraction - QIAmp DNA mini kit 
DNA quality confirmation — Beta-globin PCRs 
Three HPV-DNA detection methods -
LI-gene consensus PCRs 
GP5+/6+ primer set MY09/11 primer set PGMY09/11 primer set 
” + I 
Cycle sequencing Restriction fragment length Reverse line-blot 
polymorphism hybridization 
After collection of samples and histopathological results, total DNA extraction and 
beta-globin PCRs were performed. Three HPV-DNA detection methods were 
performed in parallel. Different genotyping methods were used according to each 
LI-gene consensus PCR. 
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3.3 Results 
3.3.1 Study population 
A total of 120 cervical cancer specimens (105 fresh frozen and 15 
paraffin-embedded) were collected from Hong Kong Chinese aged between 26-84 
years (mean: 55; SD: 13.9) and examined. Histopathological results showed that 89 
were squamous cell carcinoma, 26 were adenocarcinoma, four were adenosquamous 
carcinoma, and one was lymphoepitheliod carcinoma. Beta-globin positive PCR 
results were obtained in all samples. 
3.3.2 Optimisation of polymerase chain reactions 
The conditions of all PCRs were optimised by a set of DNA positive controls 
from a CaSki cell line (HPV 16 positive). PCR conditions including annealing 
temperature, enzyme concentration and primer concentration were optimised. 
According to the results (Figure 3.2)，analytical sensitivities were found to be around 
60 copies of viral DNA per inoculum. 
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Figure 3.2 Optimization results of GP5+/6+, MY09/11 and PGMY09/11 PCR 
A. GP5+/6+ PCR 
Lane 1 2 3 
一 n g 
B. MY09/11 PCR 
Lane 1 2 3 
C. PGMY09/11 PCR 
Lane 1 2 3 
450bp -> 
• H 
(A) Optimization results of GP5+/6+ PCR. Phil74-HaeIII is used as molecular 
marker. The expected product size of GP5+/6+ PCR is 165 bp. Lane 1 2 and 3 
are 600，60 and 6 copies/inoculum, respectively. ’ 
(B) Optimization results of MY09/11 PCR. Phi 174-HaeIII is used as molecular 
marker. The expected product size of MY09/11 PCR is 450 bp. Lane 1 2 and 3 
are 600, 60 and 6 copies/inoculum, respectively. ‘ 
(C) Optimization results of PGMY09/11 PCR. Phil74-HaeIII is used as molecular 
marker. The expected product size of PGMY09/11 PCR is 450 bp. Lane 1 2 
and 3 are 600，60 and 6 copies/inoculum, respectively. ’ 
•• 
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3.3.3 Method 1 ： GP5+/6+ PCR followed by cycle sequencing 
HPV DNA was found in 84.2% (101/120) of samples (Table 3.1). All 
GP5+/6+ PCR-positive products were typed by sequencing. GP5+/6+ 
PCR-negative samples DNA were amplified by p-globin PCR primers BGPl/2 to 
check for the integrity and adequancy of the DNA in samples (Figure 3.3). Seven 
HPV genotypes (HPV 16，18，31, 33, 35, 45 and 58) were identified. The most 
prevalent HPV type was HPV 16 (48.3%), followed by HPV 18 (19.2%), HPV 58 
(5.8%), HPV 33 (5.0%), HPV 31 (2.5%), HPV 35 and 45 (1.7%). No multiple 
infections were observed. 
3.3.4 Method 2: MY09/11 PCR followed by restriction 
fragment length polymorphism 
HPV DNA was found in 84.2% (101/120) of samples (Table 3.1). MY09/11 
PCR-negative samples DNA were amplified by |3-globin PCR primers PC03/07 to 
check for the integrity and adequancy of the DNA in samples (Figure 3.4). 
According to the result of restriction fragment length polymorphism, eight different 
genotypes of HPV (HPV 16，18，31, 33, 35, 52, 53 and 58) were identified, and one 
multiple infections (HPV 16 and 52) was observed. The most prevalent HPV types 
was HPV 16 (44.2%), followed by HPV 18 (16.7%), HPV 52 (9.2%), HPV 58 
(6.7%), HPV 33 (5.0%), HPV 35 (1.7%), HPV 31 and HPV 53 (both 0.8%). 
76 
3.3.5 Method 3: PGMY09/11 PCR followed by reverse 
line-blot hybridization 
HPV DNA was found in 95.8% (115/120) of samples (Table 3.1). A total of 15 
different HPV genotypes (HPV 16, 18，26, 31, 33，35, 39, 45, 51, 52，53, 58, 59, 66 
and 68) were identified by reverse line-blot hybridization. Beta-globin primers 
PC04/GH20 were used as internal control to check for the integrity and adequancy of 
the DNA in samples. (Figure 3.5) The most prevalent HPV types was HPV 16 
(45%), followed by HPV 18 (21.7%), HPV 52 (12.5%), HPV 58 (8.3%)； HPV 31 and 
33 (3.3%). Multiple infections was found in nine of the samples (7.5%). The 
number of HPV genotypes detected in multiple infections ranged from two to five 
(Table 3.1). HPV 52 was the most common HPV types observed in multiple 
infections, it was found in six of the nine samples with multiple infections. 
•H-
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Figure 3.3 Results of method 1 
A. GP5+/6+ PCR 
B. Beta-globin BGPl/2 PCR 
Lane 1 2 3 
345bp-> j ^ J g ^ J 
C. DNA Sequencing 
—~‘ — -
• i C . ‘ - . C C . . C . M ； - : • / �， . . !」 c； • . - . C A . . : . . 
iklilliiterfk 
(A) Gel electrophoresis result of GP5+/6+ PCR. Phil74-HaeIII is used as 
molecular marker. The expected product size of GP5+/6+ PCR is 165 bp. Lane 1 
is sample with amplified HPV DNA, it is classified as positive results. Lane 2 is 
samples without amplified HPV DNA，it is classified as negative result. Lane 3 is 
HPV DNA positive control extracted from CaSki cells. 
(B) Gel electrophoresis result of beta-globin BGPl/2 PCR. Phil74-HaeIII is used 
as molecular marker. The expected product size is 345 bp. Lane 1 to 3 are 
samples with negative GP5+/6+ PCR results. All of them show adequate DNA for 
PCR. 
(C) An example of nucleotide sequencing result of GP5+/6+ PCR product. 
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Figure 3.4 Results of method 2 
A. MY09/11 PCR 
Lane 1 2 3 
450bp-^ E j l ^ ^ ^ ^ ^ ^ S 
B. Beta-globin PC03/07 PCR 
Lane 1 2 3 
• • • • I 
C. Restriction fragment length polymorphism 
Lane 1 2 3 4 5 6 
n^ n^iii^ ^^ ^^ miiiiiimjiiiiipmiiii^ u^immummi 
(A) Gel electrophoresis result of MY09/11 PCR. Phil74-HaeIII is used as 
molecular marker. The expected product size of MY09/11 PCR is 450 bp. Lane 1 
is sample with amplified HPV DNA, it is classified as positive results. Lane 2 is 
samples without amplified HPV DNA, it is classified as negative result. Lane 3 is 
HPV DNA positive control extracted from CaSki cells. 
(B) Gel electrophoresis result of beta-globin PC03/07 PCR. Phil74-HaeIII is used 
as molecular marker. The expected product size is 509 bp. Lane 1 to 3 are 
samples with negative GP5+/6+ PCR results. All of them show adequate DNA for 
PCR. 
(C) Gel electrophoresis result of restriction fragment length polymorphism. 
Restriction enzymes Rsa I and Dde I were used to digest MY09/11 PCR products. 
Lane 1 to 3 are the same sample identified with HPV 58: lane 1 is undigested PCR 
product, lane 2 is PCR product digested by Rsa /, lane 3 is PCR product digested by 
Dde L Lane 4 to 6 are the same sample identified with HPV 16: lane 4 is 
undigested PCR product, lane 5 is PCR product digested by Rsa I, lane 6 is PCR 





































































































































































































































































3.3.6 Prevalence and genotype distribution of human 
papillomavirus infection in cervical cancer patients 
Overall 99.2% (119/120) specimens had HPV DNA detected in any methods 
(Table 3.1). HPV DNA was detected in 100% of squamous cell carcinoma, 
adenosquamous cell carcinoma and lymphoepitheloid carcinoma, and 96.2% in 
adenocarcinoma. Fifteen HPV types (HPV 16, 18, 26, 31，33’ 35, 39, 45, 51, 52, 53， 
58, 59，66 and 68) were detected in all samples by any of the three methods, 12 were 
high-risk type (HPV 16，18，31, 33，35, 39，45，51, 52, 58，59 and 68) and three 
low-risk type (26, 53，66) . For the purpose of data analysis, regardless of single or 
multiple infections, specimens were counted more than once when multiple 
infections were detected. The five most common HPV types found from cervical 
cancer in Hong Kong as revealed by a combination of the three methods in 
descending order were: HPV 16 (50%), HPV 18 (21.7%), HPV 52 (12.5%), HPV 58 
(8.3%) and HPV 33 (5.0%). HPV 16 was the most prevalent type found in cervical 
cancer, it was accounted for 50% of samples. The second most common type was 
HPV 18, it was found in 21.7% of samples. However, HPV 18 was found to be 
more prevalent among adenocarcinoma (62%) than HPV 16 (34.6%). All the five 
common types detected in samples were high-risk HPV types. Multiple infections 
were found in 9.2% of samples. 
3.3.7 Detection of multiple infections 
Of the 120 ^specimens, 11 (9.2%) had multiple infections. Method three 
detected most of them (9/11，81.8%), method two detected two of the 11 specimens 
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(18.2%), whereas method one detected none. The inability of the method one to 
detect multiple infections was likely due to the method employed to genotype the 
HPV. If multiple types are present, sequencing is not a good choice for 
identification. 
3.3.8 Sensitivity of the detection methods 
Method three was the most superior detection method in sensitivity with a 
positive rate of 96%, followed by method one and two (84.2%) (Table 3.2). Among 
all HPVs revealed, a statistically significant difference in positive rate was only 
observed for HPV 52 (p < 0.001, by chi-squared test). Method one failed to detect 
HPV 52 from all the 15 specimens that were shown to be HPV 52-positive by the 
other two methods. Method two also had a sub-optimal sensitivity for HPV 52 
when compared to method three. 
3.3.9 Comparison of prevalence rates of human 
papillomavirus genotypes 
When the prevalence rates of HPV types among cervical cancers in Hong Kong 
were ranked by the three methods (Figure 3.6), a similar result was observed for 
method two and method three: HPV 16 is the most prevalent type (44.2% and 45%, 
respectively) followed by HPV 18 (16.7% and 21.7%, respectively), HPV 52 (9.2% 
and 12.5%, respectively), HPV 58 (6.7% and 8.3%, respectively) and HPV 33 (5.0% 
and 4.2%, respectively). However, method one resulted in an under-estimation of 
the prevalence of HPV 52 from 14.6% (only second to HPV 16) to 0% among 
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cervical cancers in Hong Kong. The five most common HPVs in cervical cancer 
patients detected by method one in descending order were: HPV 16 (48.3%), HPV 18 
(19.2)，HPV 58 (5.8%), HPV 33 (5.0%) and HPV 31 (2.5%) (Table 3.2). 
3.3.10 Comparison of genotype distribution in Hong Kong 
cervical cancer patients with other geographic 
regions 
When HPV genotype distribution in Hong Kong was compared with a data from 
other geographic regions (Africa, Central and South America, Southeast Asia, Europe 
and North America), HPV 16 was the most prevalent HPV type over the world 
(Figure 3.7) accounting for 50% in Hong Kong and 40-60% in other geographic 
regions. The second most common HPV type in Hong Kong and other geographic 
regions was HPV 18, which was accounted for 21% in Hong Kong and 10-20% in 
other geographic regions. However, a high prevalence rate of HPV 52 and 58 were 
found in Hong Kong, they were accounted for 12.5% and 8.3% in Hong Kong and 
2-4% in other regions. In Hong Kong, HPV 52 and 58 were the third and forth 
most prevalent types. This was also seen in Asia, but not in other regions, where 52 
and 58 were usually the fifth and sixth most prevalent types. HPV 33 and 31 were 
the fifth and sixth most prevalent types in Hong Kong, which were accounted for 5% 
and 3.3%, respectively. The prevalence rate of HPV 31 in Hong Kong was lower 
than in other regions that HPV 31 was accounted for 5%. 
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3.3.11 Follow-up investigation of GP5+/6+ primer binding 
site in HPV 52 
Twelve HPV52-positive samples detected by method 2 or 3 were sequenced by 
ABI 3700 DNA detection system to check for the variation of sequence in GP5+/6+ 
primers binding site. Sequences obtained from the 12 HPV 52-positive samples 
were aligned with GP5+/6+ primers and HPV 52 prototype sequence (Table 3.3). 
Five mismatches were found in the alignment of GP5+ sequence with HPV 52 
prototype sequence and the alignment of GP5+ sequence with the 12 HPV 
52-positive sample sequences. Two mismatches were found in the alignment of 
GP6+ sequence with HPV 52 prototype sequence. Three mismatches were found in 
the alignment of GP6+ sequence with the 12 HPV 52-positive sample sequences. 
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Table 3.1 Distribution of HPV types among 120 Hong Kong cervical cancer 
specimens according to detection methods 
HPV type No. (%) of HPV positive specimens />-value 
N = 120 
Method 1 Method 2 Method 3 
Overall^ 101 (84.2) 101 (84.2) 115 (95.8) 0.006 
HPV 16 58 (48.3) 53 (44.2) 54 (45.0) 0.791 
HPV 18 23 (19.2) 20 (16.7) 26(21.7) 0.616 
HPV 26 0 0 1 (0.8) 0.367 
HPV 31 3(2.5) 1(0.8) 4(3.3) 0.409 
HPV 33 6 (5.0) 6 (5.0) 5 (4.2) 0.940 
HPV 35 2(1.7) 2(1.7) 4(3.3) 0.599 
HPV 39 0 0 1 (0.8) 0.367 
HPV 45 2(1.7) 0 2(1.7) 0.364 
HPV 51 0 0 1 (0.8) 0.367 
HPV 52 0 11 (9.2) 15 (12.5) <0.001 
HPV 53 0 1 (0.8) 1 (0.8) 0.605 
HPV 58 7(5.8) 8 (6.7) 10(8.3) 0.740 
HPV 59 0 0 2(1.7) 0.134 
HPV 66 0 0 1 (0.8) 0.367 
HPV 68 0 0 2(1.7) 0.134 
Multiple infections 0 1 (0.8) 9 (7.5) Not done 
HPV 16，18 0 0 1 (0.8) Not done 
HPV 16,52 0 1 (0.8) 0 Not done 
HPV 18,52 0 0 3 (2.5) Not done 
HPV 33，52 0 0 1 (0.8) Not done 
HPV 39，52 0 0 1 (0.8) Not done 
HPV 16, 18，52 0 0 1 (0.8) Not done 
HPV 31,35,58 0 0 1 (0.8) Not done 
HPV 18，31，35，58，66 0 0 1 (0.8) Not done 
•By chi-square test to assess difference in positive rates obtained by the three methods. 
卞Regardless of single or multiple infections, specimens are counted more than once when multiple 
infections are detected. 
Method 1 = GP5+/6+ PCR followed by sequencing, method 2 = MY09/11 PCR followed by 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.7 Comparison of HPV genotype distribution in cervical cancer in 
Hong Kong and other geographic regions 
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Hong Kong 
(A) World-wide HPV genotype distribution in cervical cancer. Data from a study by Clifford, 2003 
(Clifford, Smith et al. 2003b). PCR primers used to identify human papillomavirus include 
GP5+/6+ and MY09/11. Countries in Asia include Mainland China, India, Indonesia, Japan, 
Korea, Malaysia, Philippines, Taiwan, and Thailand. Number of cases = 3091 
(B) HPV genotype distribution in cervical cancer in Hong Kong. Data from current study by all 
methods combined (GP5+/6+，MY09/11 and PGMY09/11). 
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Table 3.3 Alignment of the GP5+ and GP6+ sequences with the corresponding 
regions in the LI open reading frame of HPV 52 
Sequence name and HPV type Sequence (5 ' -3 ' ) 
GP5+ TTT GTT ACT GTG GTA GAT ACT AC 
HPV 52 prototype C . .A • .T . .G C . . 
HPV 52-positive samples C ..A ..T . .G C 
GP6+ GAA AAA TAA ACT GTA AAT CAT ATT C 
HPV 52 prototype T A . . . . 
HPV 52-positive samples T GA … . 
The primer sequences are in boldface, GP5+ primer is the forward primer and GP6+ 
is the reverse primer. HPV 52 prototype (GenBank accession number NC_001592) 
is used as the reference. HPV 52-positive samples included the 12 HPV 52-postive 
samples detected by PGMY09/11 PCR. Nucleotide homology is indicated with a 





GP5+/6+ and MY09/MY11 are the most commonly used primers for detecting 
genital HPVs (Clifford, Smith et al. 2003b), whereas the PGMY09/11 primers was 
first introduced in 2000 (Gravitt, Peyton et al. 2000). HPV prevalence data 
generated by GP5+/6+ and MY09/MY11 primers constituted a major portion in 
international analyses on the risk association and vaccine priority for HPVs (Clifford, 
Smith et al 2003a; Clifford, Smith et al. 2003b; Munoz, Bosch et al. 2004). 
Although in some studies, the identification of HPVs was accomplished by 
hybridization with multiple type-specific probes which may increase the sensitivity, 
our results indicated that the GP5+/6+ PCR by itself has sub-optimal sensitivity for 
HPV 52. This is in line with a previous study reported (Qu, Jiang et al. 1997) 
where the GP5+/6+ system also failed to detect all the four samples in which HPV 52 
was detected by the MY09/11 method. HPV 52 ranked the sixth in prevalence 
among cervical cancers world-wide when a combination of results generated from 
MY09/11 and GP5+/6+ was analysed (Munoz, Bosch et al. 2003; Munoz, Bosch et 
al. 2004), and thus is regarded as having lower priority for vaccine candidate 
selection. The magnitude of under-estimation associated with GP5+/6+ system 
depends on the true prevalence of HPV 52 which is likely to have geographical and 
ethnical variations (De Vuyst, Steyaert et al 2003). In turn, the implication of these 
under-estimations depends on the true oncogenicity of HPV 52. Munoz and 
associates estimated that the odds ratio for squamous cell cervical cancer of HPV 52 
to be 200 (95% CI: 67.8-590.1) which is about half of that for HPV 16，which ranked 
� -
the fifth among high-risk HPV types (Munoz, Bosch et al 2003). The study also 
indicated that when HPV 16 existed as co-infections with another high-risk type, the 
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odds ratio increased by about one-third. Among cervical cancer patients in Hong 
Kong, a substantial proportion (40%) of HPV 52 existed as co-infections with one or 
more high-risk HPV types. The oncogenic risk attributed to HPV 52 in these 
co-infected cases, in particular its possible augmenting effect on the risk of the other 
co-existing HPV, deserves further investigations. 
This study have shown that that the overall HPV prevalence detected in 
adenocarcinoma was significantly lower than that detected in squamous cell 
carcinoma. Reasons may be due to sample DNA quality. Nearly all samples with 
adenosquamous carcinoma are paraffin-embedded samples, DNA may be destroyed 
during formalin-fixation (Chan, Chan et al 2001). Moreover, HPV 16 was the most 
common type in squamous cell carcinoma followed by HPV 18，the situation was 
reversed in adenosquamous carcinoma where HPV 18 was the most common type, 
followed closely by HPV 16. The same observation has been discussed in previous 
studies (Nakagawa, Yoshikawa et al. 1996; Parkin, Pisani et al 1999). Compared 
to HPV 16，HPV 18 has been shown to be associated with increasing oncogenic 
potential in cell culture, as well as a more rapid transition to malignancy and a poorer 
prognosis of cancer patients (Barbosa and Schlegel 1989; Burger, Monk et al. 1996). 
Given the fact that columnar cells are less accessible to develop adenosquamous 
carcinoma, and possibly less susceptible to HPV infections than the squamous tissue 
of squamous cell carcinoma, the establishment of adenosquamous carcinoma may 
require a relatively more aggressive infection (Hildesheim, Hadjimichael et al 1999; 
Schwartz, Daling et al. 2001). 
， Multiple HPV infections are not common in cervical cancer cases. Although 
our study design was not able to provide a fair comparison on the ability of the three 
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primers sets to detect multiple infections, the potential problem of certain HPV 
detection systems in under-estimating co-infections should be considered when 
assessing oncogenic risk and when assessing the priority as a vaccine candidate, as 
well as when projecting the cost-benefit of future cervical cancer vaccines. 
Same mismatches were found in the alignment of GP5+ sequence with the 
reference HPV 52 sequece and the alignment of GP5+ sequence with the HPV 52 
sequences detected in this study. However, an addition mismatch was found in the 
alignment of GP6+ sequence with the HPV 52 sequences detected, in this study. 
The position of this addition mismatch is near to the 3' end of GP6+ primer, which 
may affect the binding efficiency of the GP6+ primer to HPV 52. So, it can explain 
the reason why GP5+/6+ PCR is sub-optimal in the detection of HPV 52 in this 
study. 
When HPV genotypes in cervical cancer in Hong Kong were compared to other 
geographic regions, HPV 16 was clearly the predominant type followed by HPV 18. 
The only one region-specific variation is the high prevalence rates of HPV 52 and 58 
in Asia and Hong Kong, and decrease in HPV 31 prevalence. This unusual high 
prevalence rate of HPV 52 and 58 was also found in Japan, South Korea and Taiwan 
(Pao, Kao et al. 1993; Maehama, Asato et al. 2002; Shin, Lee et al. 2003). 
In conclusion, data from this study indicates that the PGMY09/11 is the most 
sensitive method for the detection of HPV DNA. HPV 52 infection is 
under-estimated when GP5+/6+ is used as the detection tool, and the result may 
affect the analyses on the risk association and vaccine priority for HPVs. Two 
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globally uncommon prevalent HPV types - HPV 52, 58 are prevalent among Hong 
Kong Chinese women with cervical cancer (12.5% and 8.3%, respecitively) and 
multiple infections were not common in Hong Kong women with cervical cancer. 
HPV 52 and 58 has high priorities in vaccine selection for the Chinese population. 
Further study will be focused on HPV genotype distribution and prevalence in 
Hong Kong women with HGSIL. Detection of HPV is suggested for the triage of 
patients with HGSIL after treatment to aid the prediction of CIN recurrence; further 
study can focus on the usefulness of HPV detection for the prediction of CIN 
recurrence of HGSIL patients after treatment. 
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Cficipter ^our 
Study II 一 物St-treatment ToCCow-up 




This study is to investigate the prevalence and genotype distribution of HPV 
infection in patients with high-grade squamous intraepithelial lesions, and to assess 
the relationship between HPV persistence and recurrence of cervical lesions 
following local surgical treatment. 
4.2 Study plan 
Patients with high-grade cervical abnormalities (CIN II to CIN III) and treated 
by loop electrosurgical excision procedure (LEEP) in the Prince of Wales Hospital, 
Shatin, Hong Kong were recruited in this study. Before treatment, histopathological 
and colposcopic examinations were performed to confirm the diagnosis of cervical 
intraepithelial neoplasia. A cervical scrape sample was collected before LEEP for 
HPV detection. After treatment, LEEP biopsies were collected for 
histopathological examination. The involvement of excision margin was recorded. 
Patients were followed every four months for one year. In each visit, cytology 
screening was performed. Biopsy samples were taken when indicated to confirm 
CIN recurrence by histopathological examination. Treatment by LEEP was 
repeated for patients with CIN recurrence. At 12 months after LEEP, in addition to 
cytological examination, a cervical scrape sample was collected from all patients for 
HPV detection. At the same visit, an exit colposcopic examination was performed 
for all patients to define the outcome of LEEP treatment. Histopathological 
examination was performed for any abnormalities detected by the exit colposcopy. 
Details of the laboratory methods are described in Chapter 2: Materials and Methods. 
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4.3 Results 
4.3.1 Study population 
A total of 407 Hong Kong Chinese women were initially recruited in this study. 
Two hundred and two patients did not complete all the follow-up visits. Three 
patients had CIN III recurrence during follow-up. These three patients received a 
repeat-operation. As a result, 202 patients, aged between 25-62 years (mean: 40; 
SD: 7), had a pre-treatment and 12-month post-treatment samples collected for HPV 
analysis. 
Histopathological examinations on biopsy samples collected before treatment 
showed that 49 of 202 (24%) study patients had CIN II and 153 of 202 (76%) study 
patients had CIN III. Histopathological examination of LEEP biopsies revealed 46 
of 202 (23%) samples with excision margins containing neoplastic cells, and 156 of 
202 (77%) samples had cleared margins. 
At the 12-month follow-up visit, two CIN recurrence cases were detected by 
colposcopic examination and subsequently confirmed by histopathological 
examination. Treatment by LEEP was repeated for these two cases. 
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4.3.2 The prevalence and genotype distribution of human 
papillomavirus infection before treatment 
HPV DNA was detected in 162 of the 202 (80%) study patients. HPV 
prevalence rates were 82% (125/153) and 76% (37/49) for patients with CIN III and 
CIN II，respectively (Table 4.1). Single HPV infection was found in 114 of 202 
(56%) patients, multiple HPV infections were found in 48 of 202 (24%) patients. 
The number of HPV genotypes detected in multiple infections ranged from two to 
five (Table 4.2). The two most common multiple infections were HPV 16，52 
(11/48) and HPV 52, 58 (5/48). 
Together with single and multiple infections, 28 different HPV genotypes were 
identified in the 202 patients (Table 4.3). Thirteen were high-risk types and 15 
were low-risk types. The six most common HPV genotypes were HPV 16 (34%), 
HPV 52 (19%), HPV 58 (11%), HPV 18 (9%), HPV 33 (8%), and HPV 31 (5%) 
(Figure 4.1). All of them are classified as high-risk HPV genotypes. Other 
detected HPV genotypes include HPV 6，11，26, 31, 39, 42，45，51, 53, 54, 56, 61, 62, 
64, 66, 67, 68，70，72, 82, 84，and CP6108. 
The same HPV genotype prevalence order was found in patients with CIN III 
when compared as a whole group, but a statistically insignificant different HPV 
genotype prevalence order was found in patients with CIN II. The six most 
common HPV genotypes in patients with CIN II were HPV 52 (30%), HPV 58 (23%), 
HPV 16 (15%), HPV 33 (13%), HPV 18 (10%), and HPV 31 (5%) (Figure 4.2). 
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4.3.3 Persistent human papillomavirus infection 
For the purpose of analysis in this study, persistent HPV infection was defined 
when the same HPV genotype was detected before and at 12-month after LEEP, 
regardless of a single or multiple infections. The prevalence rate of HPV infection 
at 12-month was 12% (25/202). Persistent HPV infection was found in 4% (9/202) 
of patients. Two of the nine patients had recurrence of CIN detected at 12-month 
after initial treatment (Table 4.4). HPV 16, 18, 52, 56, 68 and 84 were found in the 
persistent infection. HPV 16 (3/9) and 52 (3/9) accounted for the two most 
common HPV genotypes in the persistent infections. 
4.3.4 Risk-factors associated with persistent human 
papillomavirus infection 
4.3.4.1 Excision margin status 
Neoplastic cells were detected in the excision margins of 46 (23%) patients. 
Five of these 46 patients showed persistent HPV infection. Two of the five patients 
with persistent HPV infection had CIN recurrence (Table 4.4). There was no 
significant association between the involvement of neoplastic cells in excision 
margin and the persistence of HPV infection {p = 0.12, by Fisher's exact test) (Table 
4.5). 
4.3.4.2 Multiple human papillomavirus infections 
Seven of nine patients (77%) with persistent HPV infection showed multiple 
HPV infections before treatment (Table 4.4). The most common HPV genotype 
99 
found in multiple infections was HPV 52 (5/7), followed by HPV 16 (4/7). Table 
4.5 shows the significant association between multiple HPV infections and persistent 




























































































































































































































Table 4.2 Distribution of HPV genotypes in multiple infections 
HPV type No. of patients 
"Multiple infections with HPV 11, 16 1 
two HPV types HPV 16，18 1 
HPV 16’ 31 2 
HPV 16 ,45 1 
HPV 16, 52 6 
HPV 16，54 1 
HPV 16, 56 1 
HPV 16’ 68 1 
HPV 16’ 70 1 
HPV 18, 52 1 
HPV 18, 62 1 
HPV 18，84 1 
HPV 31, 45 1 
HPV 33,45 1 
HPV 33，52 2 
HPV 33, 53 1 
HPV 33’ CP6108 1 
HPV 39, 82 1 
HPV 52, 53 1 
HPV 52, 58 3 
HPV 53，61 1 
HPV 58，68 1 
HPV 59，84 1 
Multiple infections with HPV 6, 16,58 1 
three HPV types HPV 16，45’ 52 1 
HPV 16, 52, 84 1 
HPV 31，59，84 1 
HPV 33, 54, 62 1 
HPV 52, 56, 58 1 
HPV 52, 56’ 59 1 
HPV 52, 72’ 84 1 
HPV 61, 66, 82 1 
Multiple infections with HPV 11, 16，18, 58 1 
four HPV types HPV 16, 18,52,84 1 
HPV 16, 18,53,58 1 
‘ HPV 16,52,58,64 1 
HPV 26,42,58,66 1 . 
HPV 51, 56，58’ 61 1 
Multiple infections with um, i/；� / : ” c ’ / : o 1 ~ 二 “ HPV 16, 26, 33，52, 68 
Five HPV types 
Thirty-two patients had multiple infections with two HPV types, nine patients had multiple infections 
with three HPV types, six patients had multiple infections with four HPV types, and one patient had 
multiple infections with five HPV types. 
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Table 4.3 Genotype distribution of HPV before treatment 
Single infection Multiple infections All infection 
N(%) N(%) N(%) 
HPV 16 45 (39.4) 23 (47.9) 68^4^ 
HPV 18 11(9.6) 7(14.6) 18(11.1) 
g. HPV 31 7(3.5) 4(2) 11(6.8) 
HPV 33 10(6.1) 7(14.6) 17(10.5) 
§ HPV 39 1(<1) 1(<1) 2(1.2) 
> HPV 45 1(<1) 4(8.3) 5(3.1) 
主 HPV 51 0 1(<1) 1(<1) 
S HPV 52 18 (15.8) 21 (43.8) 39(24.1) 
•C HPV 56 0 4 (8.3) 4 (2.5) 
4 HPV 58 12(10.5) 11 (22.9) 23 (14.2) 
£ HPV 59 0 3 (6.3) 3 (1.9) 
HPV 68 2 (1.8) 3 (6.3) 5 (3.1) 
HPV 82 0 1 (<1) 1 (<1) 
HPV 6 3(2.6) 4(8.3) 7(4.3) 
HPV 11 0 2(4.1) 2(1.2) 
HPV 26 0 2(4.1) 2(1.2) 
g HPV 42 0 1 (<1) 1 (<l) 
Z HPV 53 0 4 (8.3) 4 (2.5) 
i HPV 54 0 2(4.1) 2(1.2) 
> HPV 61 0 4(8.3) 4(2.5) 
X HPV 62 2(1.8) 2(4.1) 4(2.5) 
HPV 64 0 1 (<1) 1 (<l) 
-M HPV 66 1(<1) 3 (6.3) 4(2.5) 
I HPV 61 1 (<1) 0 1 (<i) 
^ HPV 70 0 1 (<1) 1 (<i) 
HPV 72 0 1 (<1) 1 (<i) 
HPV 84 0 6(12.5) 6(3.7) 
CP6108 0 1 (<1) 1 (<i) 
�Human papillomaviruses are classified into high-risk and low-risk types according to Munoz et al 
2003. The total number of patients had single infection is 114，multiple infections is 48. ’ 
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Figure 4.1 The six most common HPV genotypes detected before treatment 
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4.4.1 Prevalence and genotype distribution of human 
papillomavirus in high-grade cervical neoplasia 
Numerous studies have shown that there is a highly significant association 
between persistent infection with high-risk HPVs and high-grade lesions. The 
detection rate of HPV DNA was documented to be 85-95% of high-grade lesions, of 
which 50-65% are of high-risk type HPVs (Kaufman, Adam et al. 1997; Kjellberg, 
Wiklund et al. 1998). The HPV prevalence rate in this study was slightly lower 
(80%) than that reported by other authors (Gonzalez-Sanchez et al” 2002; ATLS 
group, 2000). Reasons may be due to poor DNA quality or presence of PCR 
inhibitors. However, the extraction methods used in this study are the physical 
extraction method by heating the samples at 95''C for 10 min and the chemical 
extraction using the Qiagen extraction kit. Physical extraction was performed as the 
primary extraction method for all cervical scrapes samples. Cervical scrapes 
samples with a negative-p-globin PCR result were extracted again by chemical 
extraction in order to eliminate the problems of poor DNA quality and presence of 
PCR inhibitors. A study performed by Chan et al (2001) showed that DNA 
extraction was most efficient when the Qiagen spin column was used. This method 
�yielded the highest positive predictive value when a housekeeping gene was used as 
an indicator of successful viral DNA extraction. It seems that the low prevalence 
rate may be due to other reasons. One possible reason may be the removal of 
tumour tissue by biopsy before treatment. Histopathological examination of some 
patients showed that no residual lesion was detected in the LEEP biopsies. It is 
likely that the size of the cervical lesion in the patient is very small and the lesion 
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was cleared by biopsy in the histopathological examination, so that no HPV DNA 
was detected in those patients before LEER 
Compared with the results in study I, HPV infection is more prevalent in 
cervical cancer (99%) than in HGSIL (80%). HPV 16 and 18 are the most 
prevalece types in both cases. Result shows that it is more prevalent in cervical 
cancer (50% and 20%, respectively) than in HGSIL (34% and 5%, respectively). 
This result is concordant to previous studies (Remmink, Walboomers et al. 1995; 
Bollen, Tjong et al. 1997; Kaufman, Adam et al 1997; Kjellberg, Wiklund et al. 
1998; Bosch, Lorincz et al. 2002). Some of the studies suggested that HPV 16 is 
more prevalent in cervical cancer than other HPVs because HPV 16 can evade the 
host immune response more efficiently, and so it has a greater potential to induce 
malignant transformation. 
HPV 52 and 58 are the second (19%) and third (11%) common HPV genotypes 
found in patients with HGSIL, respectively. These unusual high prevalence rates of 
HPV 52 and 58 support the findings in study I. According to the results in study I, 
HPV 52 and 58 are the third (12%) and fourth (8.3%) common HPV genotypes 
found in patients with cervical cancer, respectively. Both of them have a high 
‘priority as vaccine candidate for the women population in Hong Kong. Moreover, 
HPV 52 and 58 are more prevalent in patients with HGSIL than in patients with 
cervical cancer, which suggest that HPV 52 and 58 have a relatively lower oncogenic 
potential and less able to establish persistant infection than HPV 16. Comparative 
results have shewn in a study by Clifford and associates (2003), HPV 52 and 58 are 
not common in patients with HGSIL world-wide. Their prevalence rates are below 
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7%. They found that HPV 58 was ranked as the fifth and HPV 52 was ranked as 
the sixth most common HPV genotypes in patients with HGSIL. 
This unusual high prevalence rate of HPV 52 and 58 is also found in Japan, 
South Korea and Taiwan (Pao, Kao et al 1993; Maehama, Asato et al 2002; Shin, 
Lee et al 2003), but less prevalent was found in South East Asia, including India, 
Indonesia, Philippines and Thailand (Takami, Kondoh et al. 1991; Chichareon, 
Herrero et al. 1998; Ngelangel, Munoz et al. 1998; Rajkumar, Franceschi et al. 
2003). 
The six most common HPV genotypes in patients with CIN III were HPV 16 
(34%), HPV 52 (19%), HPV 58 (11%), HPV 18 (9%), HPV 33 (8%), and HPV 31 
(5%). However, the six most common HPV genotypes in patients with CIN II were 
HPV 52 (30%), HPV 58 (23%), HPV 16 (15%), HPV 33 (13%), HPV 18 (10%), and 
HPV 31 (5%). HPV 52 and 58 were more prevalent in patients with CIN II than 
paitents with CIN III, and HPV 16 was more prevalent in patients with CIN III than 
patients with CIN 11. This may be due to the oncogenic potential between HPV 
types are different. HPV 16 has higher oncogenic potential than HPV 52 and HPV 
58. Therefore, HPV 16 was more prevalent in patients with CIN III, HPV 52 and 
� 5 8 were more prevalent in patients with CIN II. 
4.4.2 Risk factors for cervical intraepithelial neoplasia 
recurrence 
The frequency of positive excision margin in our study was 23% and two of the 
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patients with positive excision margin had CIN recurrence at 12-months after 
treatment. The percentage of patients with positive excision margin obtained in this 
study was within the range reported by others (10%-46%) (Bistoletti, Zellbi et al. 
1988; Lapaquette, Dinh et al 1993; Felix, Muderspach et al. 1994; Kanamori, 
Kigawa et al 1998; Jain, Tseng et al 2001). Most of the studies clearly 
demonstrate that positive margins significantly increase the risk of recurrence 
(Bistoletti, Zellbi et al 1988; Lapaquette, Dinh et al. 1993; Felix, Muderspach et al 
1994; Kanamori, Kigawa et al 1998; Jain, Tseng et al 2001). However, the 
number of patients with CIN recurrence in the current study is too small for analysis, 
the association between excision margin status and CIN recurrence thus therefore 
cannot be analysed. 
The same limitation was found in the association between persistent HPV 
infection and CIN recurrence. It is a well-established observation that there is a 
highly significant association between persistent infection of high-risk HPV and the 
development of CIN disease (Nobbenhuis, Walboomers et al 1999; ter Harmsel, 
Smedts et al 1999). A study by Nagai and co-workers (2000) showed that 46% of 
patients with persistently positive HPV DNA developed CIN recurrence from 4 to 10 
months after treatment by conization (Nagai, Maehama et al 2000). However, the 
�number of patients with CIN recurrence in the current study was too few to assess its 
association with persistent HPV infection. 
The reasons of low CIN recurrence cases in this study may be due to the length 
of study period. After treatment, most of the recurrent CIN are expected to occur 
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with a 30-month period (Bodner, Bodner-Adler et al. 2002; Milojkovic 2002). The 
length of current study period was set at 12 months after treatment, which was 
probably not enough to catch all CIN recurrence cases. Therefore, if the study 
period could be extended to 30 months, more recurrence cases may be detected. 
Moreover, it is observed that there are different ways to define persistent HPV 
infection. These are (1) presence of HPV DNA regardless of the type, (2) presence 
of the same HPV genotype, and (3) presence of the same HPV genotype with the 
same variant (Bollen, Tjong et al 1996). In the current study, we used the second 
definition. The genotype of HPV infection was typed by reverse line-blot 
hybridization assay, but the variant of HPV infection cannot be assessed. There are 
two advantages of using this definition. First, it can exclude the re-infection of a 
new different HPV type. Results obtained according to the second definition are 
more accurate than the first definition. Second, it is easier to get sufficient samples. 
It would be rather di伍cult to analyse samples harbouring the same HPV type of the 
same variant, as this would make the sample size very small thus making data 
analysis difficult. 
The presence of multiple HPV types in one individual is common and several 
�studies have attempted to define the role of multiple HPV infections in HPV 
persistence. Previous studies have found that infection with multiple HPV types 
were associated with persistence of HPV infection in sexually-active women (Ho, 
Bierman et al 1998). This finding is supported by Woodman et al. (2001), who 
found that simultaneous infection with HPV 16 and another type resulted in longer 
duration of detectable HPV 16 than did infection with HPV 16 alone. However, 
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other authors have reported that the presence of multiple HPV types does not appear 
to influence HPV persistence. In one study, time to clear an HPV infection was 
compared among women with and without co-infection with other HPV types and 
there was no significant difference in the duration of infection seen between the two 
groups (Rousseau, Pereira et al. 2001). In another study, the role of HPV 16 in 
persistent infection along with other HPV types was investigated and no association 
was found between presence of HPV 16 and persistency of other HPV infections 
(Liaw, Glass et al. 1999). However, Bachtiary et al (2002) and van der Graafe^ al. 
(2002) suggested that multiple HPV infections are associated with increased risk for 
cervical cancer progression. It is not clear if this observation is due to differences in 
host susceptibility, interactions between the virus or the independent probability of 
progression associated with each viral type. The current study showed that multiple 
HPV infections was associated with persistent infections of patients after LEEP, one 
possible explanation may be due to residual neoplastic cells not removed after LEEP. 
This result supports the studies by Ho et al. (1998) and Woodman et al. (2001) that 
multiple infections was associated with persistent HPV infection. 
In conclusion, HPV 52 and 58 are common in patients with high-grade CIN 
lesions, but the oncogenic potential of HPV 52 and 58 appears to be lower than that 
� o f HPV 16 and 18. The results of this study also suggest that there might be a role 
for a HPV DNA test at the follow up period. Results showed that a positive HPV 
test may predict HPV persistent infection, and assist the early detection of CIN 
recurrence. However, cytology and colposcopy may still be needed in order to rule 
out false positive and false negative results. Further studies will focus on the 






Study III 一 Investigation of Human 
(papiCComavirus 52 Sequence Variation 
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5.1 Objective 
HPV E6 and E7 proteins play an important role in the development of cervical 
cancer. Most studies on sequence variation have been based on HPV 16，which is 
the most prevalent high-risk type of HPV. HPV 52 has been found to be prevalent 
in patients with different degrees of cervical intraepithelial lesions in Hong Kong as 
determined in study I and 11. Therefore, we examined the sequence variation of 
HPV 52 variants in Hong Kong. 
5.2 Study plan 
HPV 52-positive samples detected from study I, II and previous studies 
conducted by our department were retrieved for sequencing analysis. For patients 
with more than one HPV 52-positive samples, the first collected sample was 
analysed. 
For this study, HPV E6 and E7 open reading frames were analysed. The 
genome sequence of prototype HPV 52 was used as the reference sequence in this 
study. Nucleotide positions described were according to the prototype NC—001592. 
All sequencing results were compared with published HPV sequences using the 
‘ BLAST programme with sequences available in the GenBank 
(http://www.ncbi.nlm.nih.gov/blast). 
All experimental procedures were described previously in Chapter Two: 
Materials and Methods. 
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5.3 Results 
5.3.1 Study population 
A total of 66 cervical neoplasia specimens (9 fresh frozen tissues, 1 
paraffin-embedded tissue and 56 cervical scrapes) were collected from Hong Kong 
Chinese women aged between 25-84 years (mean: 46; SD: 13.6) and examined. Of 
the 66 cases, 10 were invasive cervical carcinoma, 26 were CIN III, 17 were II, and 
13 were CIN I. HPV genotyping results were performed using the reverse-line blot 
hybridization assay. Results showed that 38 samples were of a single HPV 52 
infection and 28 samples were of multiple infections including HPV 52. The 
multiple infections are showed in Table 5.1. 
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Table 5.1 List of multiple infections 
Multiple infections 
HPV types No. of patients 
HPV 16，52 6 
HPV 18, 52 3 
HPV 33, 52 3 
HPV 51, 52 1 
HPV 52, 55 1 
HPV 52，58 2 
HPV 52，59 2 
HPV 52，84 1 
HPV 52, CP6108 1 
HPV 16, 45, 52 1 
HPV 16, 52, 73 1 
HPV 16, 52, 84 1 
HPV 52, 70，83 1 
HPV 16，52，58，64 1 
HPV 52,61,72, 84 1 
HPV 16，18,29, 52, 59 1 
HPV 33，52’ 53，66，81 1 
Multiple HPV infections were detected by reverse-line blot hybridization assay. Except HPV 81, 82 
and 84, all detected HPV types were high-risk type. 
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5.3.2 Nucleotide sequence variations 
5.3.2.1 Human papillomavirus 52 E6 open-reading frame 
Six of the 66 samples (9%) showed 100% sequence similarity with the HPV 52 
E6 sequence prototype and were thus referred to as "prototype-like". The 
remaining 60 isolates (91%) were grouped into 12 different variants and named 
according to their frequency of occurrence as HPV52-E6-HK1 to HPV52-E6-HK12 
(Table 5.2). The maximum number of variations for any variant was five. 
Mutations generating a frame-shift or a premature stop codon were not observed. 
Forteen nucleotide sequence substitutions were found over the 447-bp E6 ORF 
(nt 102- 548). Two hot-spot variations (G to T) and (A to G) were found in nt-350 
(91%) and nt-379 (86.3%). Other sequence variations were A to G substitution at 
nt-177, G to C substitution at nt-194, A to C substitution at nt-219, G to T 
substitution at nt-220, C to T substitution at nt-237, G to A substitution at nt-356, A 
to C substitution at nt-378，G to C substitution at nt-391, A to G substitution at nt-446, 
C to A substitution at nt-467, A to G substitution at nt-530, C to G substitution at 
nt-531. The average chance of having a nucleotide sequence deviation from 
prototype in HPV 52 E6 was five substitutions per 1000 bp (Table 5.2). 
Among the 14 nucleotide substitutions, four were non-synonymous with amino 
acid substitutions. The lysine to arginine substitution at aa-93 (K93R) generated by 
a A to G nucleotide substitution at nt-379 was the most commonly detected 
substitution found in 86.3% isolates. Other predicted amino acid substitutions were 
� ‘ 
I26V, R40I, S97T, and N122K. 
119 
HPV52-E6-HK1 was the most prevalent HPV 52 E6 variants found in patients. 
69.7% (47/66) of 66 samples showed HPV52-E6-HK1 variant in E6 ORF (Table 5.3). 
Two nucleotide substitutions were detected at nt-350 (G to T) and nt-379 (A to G). 
The nucleotide substitution at nt-379 (A to G) was a non-synonymous substitution. 
Amino acid substitution (lysine to arginine) at aa-93 (K93R) was predicted by this 
nucleotide substitution. However, there was no significant association between the 
most prevalent HPV 52 E6 variants (HPV52-E6-HK1) and the severity of cervical 









































































































































































































































































































































































































































































































































































































































































































































































































































































Table 5.3 Distribution of HPV 52-E6 variants according to the degree of 
cervical lesions 
HPV 52 E6 variant No. (%) of 66 HPV 52-positive cervical neoplasia sample 
CINI CINII CIN III i r c Overall 
(n=13) (n=17) (n = 26) (n=10) (n = 66) 
HPV 52-E6-HK1 10(15.1) 12(18.2) 18(27.3) 6(9.1) 46(69.7) 
HPV 52-E6-HK2 0 1 (1.5) 0 2 (3) 3 (4.5) 
HPV 52-E6-HK3 0 0 2(3) 0 2(3) 
HPV 52-E6-HK4 0 0 1 (1.5) 0 1 (1.5) 
HPV 52-E6-HK5 0 0 1 (1.5) 0 1 (1.5) 
HPV 52-E6-HK6 0 0 1 (1.5) 0 1 (1.5) 
HPV 52-E6-HK7 0 1 (1.5) 0 0 1 (1.5) 
HPV 52-E6-HK8 0 1 (1.5) 0 0 1 (1.5) 
HPV 52-E6-HK9 0 0 0 1 (1.5) 1 (1.5) 
HPV 52-E6-HK10 1 (1.5) 0 0 0 1 (1.5) 
HPV 52-E6-HK11 0 0 1 (1.5) 0 1(1.5) 
HPV 52-E6-HK12 0 0 0 1 (1.5) 1 (1.5) 
Prototype-like 2(3) 2(3) 2(3) 0 6(9) 
isolates 
CIN I, II or III = cervical intraepithelial neoplasia grade I, II or III, respectively; ICC 
=invasive cervical cancer. Nucleotide sequence and amino acid substitution of 
HPV 52 E6-0RF variants were showed in Table 5.2. Prototype-like isolates refer to 
those without nucleotide sequence deviation from prototype over HPV 52 E6-0RF. 
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Table 5.4 Association between HPV 52-E6-HK1 variants and cervical 
neoplasia 
Cervical neoplasia 
CIN I-III ICC 
(n = 56) (n = 10) Rvalue 
HPV 52 E6 variants 
HPV52-E6-HK1 40 6 
Non HPV52-E6-HK1 16 4 
CIN I-III 二 cervical intraepithelial neoplasia grade I，II and III. ICC = Invasive 
cervical carcinoma. Association evaluated by Fisher's exact test. Double-sided p 
< .05 was considered to be significant. 
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5.3.2.2 Human papillomavirus 52 E7 open-reading frame 
Six of the samples (9%) showed 100% sequence similarity with the HPV 52 E7 
sequence prototype and were thus referred to as "prototype-like". The remaining 60 
isolates were grouped into five different variants and named according to their 
frequency of occurrence as HPV52-E7-HK1 to HPV52-E7-HK5, respectively (Table 
5.5). The maximum number of variations for any variant was nine. Mutations 
generating a frame-shift or a premature stop codon were not observed. 
Twelve nucleotide sequence substitutions were found over the 300-bp E7 ORF 
(nt 553-852). Two hot-spot variations (C to T) and (A to G) were found at nt-751 
(86.3%) and nt-801 (90.9%) of E7 ORF. Other sequence variations were T to A or 
C substitution at nt-573, C to T substitution at nt-595, C to T substitution at nt-662, A 
to G substitution at nt-706, G to A substitution at nt-707, T to G substitution at nt-727, 
C to T substitution at nt-733, G to A substitution at nt-742, C to A substitution at 
nt-754, T to G substitution at nt-848. The average chance of having a nucleotide 
sequence deviation from prototype in HPV 52 E7 was seven substitutions per 1000 
bp (Table 5.5). 
A total of six non-synonymous amino acid substitutions were found. All of 
them were observed in HPV 52-E7-HK2 variant. The amino acid changes observed 
in the isolates were threonine to isoleucine amino acid substitution at aa-37 (T37I) 
generated by a C to T nucleotide substitution at nt-662, serine to aspartic acid amino 
acid substitution at aa-52 (S52D) generated by a G to A nucleotide substitution at 
nt-707, tyrosine to aspartic acid amino acid substitution at aa-59 (Y59D) generated 
by a T to G nucleotide substitution at nt-727, histidine to tyrosine amino acid 
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substitution at aa-61 (H61Y) generated by a C to T nucleotide substitution at nt-733, 
aspartic acid to asparagines amino acid substitution at aa-64 (D64N) generated by a 
G to A nucleotide substitution at nt-742，and leucine to arginine amino acid 
substitution at aa-99 (L99R) generated by a T to G nucleotide substitution at nt-848. 
HPV52-E7-HK1 was the most prevalent HPV 52 E7 variants found in patients. 
80.3% (53/66) of 66 samples showed HPV52-E7-HK1 variant in E7 ORF (Table 5.6). 
Two nucleotide substitutions were detected at nt-751 (C to T) and nt-801 (A to G). 
Both of them were silent nucleotide substitution. There was no significant 
association between the most prevalent HPV 52 E7 variants (HPV52-E7-HK1) and 
the severity of cervical neoplasia {p= 0.67, by Fisher's exact test) (Table 5.7). The 
second most prevalent HPV 52 E7 variant in patients was HPV52-E6-HK2, it 
account for 4.5% (3/66) of 66 patients (Table 5.6). Nine nucleotide substitutions 
were detected at nt-573 (A to C), nt-662 (C to T), nt-706 (A to G), nt-707 (G to A), 
nt-727 (T to G), nt-733 (C to T), nt-742 (G to A), nt-801 (A to G) and nt-848 (T to G). 
Five of nine nucleotide substitution were non-synonymous substitution. The 
predicted amino acid substitution were T37I, S52D, Y59D, H61Y, D64N and L99R. 
HPV52-E6-HK2 variant was observed in one patient with invasive cervical cancer, 
and two patients with CIN III. 
H-
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Table 5.5 Nucleotide sequence variations in the E7 ORF of HPV 52 detected in 66 Hong Kong women 
Nucleotide sequence Predicted amino acid substitution 
HPV 52 E 7 - O R F N o . of 5 5 6 7 7 7 7 7 7 7 8 8 
variant isolates 7 9 6 0 0 2 3 4 5 5 0 4 
‘ 3 5 2 6 7 7 3 2 1 4 1 8 
Prototype-like 6 T C C A G T C G C C A T 
HPV 52-E7-HK1 53 - - - - - - - - T - G -
HPV 52-E7-HK2 3 A - T G A G T A - - G G T37I / S52D / Y59D / H61Y/ D64N / L99R 
HPV 52-E7-HK3 2 - - - - - - - - T A G -
HPV 52-E7-HK4 1 C - — - - - - - T - G -
HPV 52-E7-HK5 1 - T - - - - - - T - G -
HPV 52 prototype (GenBank accession number NC—001592) is used as the reference. Nucleotide positions where variations were detected are 
written vertically across the top (Red-font). Positions at which no variation was found are marked with dashes. Black-font = a silent 
nucleotide substitution; highlighted-font = non-synonymous substitution. The one-letter amino acid code is used. The position of amino acid 
change is stated numerically. The letter preceding this number refers to the reference amino acid and the letter following it refer to its 
substitution. Prototype-like isolates refer to those without nucleotide sequence deviation from prototype over the E7 ORF. 
126 
Table 5.6 Distribution of HPV 52 E7 variants according to the degree of 
cervical lesions 
HPV 52 E7 variant No. (%) of 66 HPV 52-positive cervical neoplasia sample 
CIN I CIN II CIN III Overall 
(n=13) (n=17) (n = 26) (n=10) (n = 66) 
HPV 52-E7-HK1 11 (16.6) 13 (19.7) 20 (30.3) 9(13.6) 53 (80.3) 
HPV 52-E7-HK2 0 0 2(3) 1 (1.5) 1 (4.5) 
HPV 52-E7-HK3 0 1 (1.5) 1 (1.5) 0 2 (3) 
HPV 52-E7-HK4 0 1 (1.5) 0 0 1 (1.5) 
HPV 52-E7-HK5 0 0 1 (1.5) 0 1 (1.5) 
Prototype-like 2(3) 2(3) 2(3) 0 6(9) 
isolates 
CIN I，II or III 二 cervical intraepithelial neoplasia grade I，II or III, respectively; ICC 
二 invasive cervical cancer. Nucleotide sequence and amino acid substitution of 
HPV 52 E7-0RF variants were showed in Table 5.5. Prototype-like isolates refer to 
those without nucleotide sequence deviation from prototype over HPV 52 E7-0RF. 
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Table 5.7 Association between HPV 52-E7-HK1 variants and cervical 
neoplasia 
Cervical neoplasia 
CIN I-III ICC 
(n = 56) (n = 10) 尸 alue 
HPV 52 E7 variants 
HPV52-E7-HK1 44 9 
Non HPV57-E6-HK1 12 1 
CIN I-III = cervical intraepithelial neoplasia grade I, II and III. ICC = Invasive 
cervical carcinoma. Association evaluated by Fisher's exact test. Double-sided p 
< .05 was considered to be significant. 
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5.3.2.3 Comparison of nucleotide sequence variations in HPV 52 
E6 and E7 open-reading frame 
The neuclotide sequence variations in both E6 and E7 ORF of HPV 52 detected 
in 66 Hong Kong women were showed in Table 5.8. Six (9.1%) of the 66 patients 
showed prototype-like nucleotide sequence in both E6 and E7 ORF. Four of the six 
samples showed single HPV 52 infection, and two of the six samples showed 
multiple HPV 52 infection. No prototype-like nucleotide sequence was observed in 
sample with invasive cervical cancer. Thirty-seven (56%) of the 66 patients showed 
HPV52-E6-HK1 variant and HPV52-E7-HK1 variant in E6 ORF and E7 ORF, 
respectively. 
The comparison of E6 and E7 gene sequence homology between HPV 52 and 
seven HPV prevalent types (HPV 16, 18，31, 33, 35, 45 and 58) were showed in 
Table 5.9. The percentages of sequence homology between HPV 52 and the seven 
HPV prevalent types in E6 ORF were ranged from 57%-74.7%. The percentages of 
sequence homology between HPV 52 and the seven HPV prevalent types in E7 ORF 
were ranged from 55.7%-77.7%. The maximum number of variations for any 
variant in HPV 52 E6 gene was five (1%), and the maximum number of variations 
. f o r any variant in HPV 52 E7 gene was nine (3%). Therefore, the HPV type 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Sequence variations were commonly found in Hong Kong patients with cervical 
abnormality. More than 90% of samples showed sequence variation in both HPV 
52 E6 and E7 genes. E6 and E7 genes play an important role in cervical cancer 
development. However, current study showed that ther is no association between 
HPV 52 E6 and/or E7 variants and the development of cervical cancer. 
Reasons may due to the mutations only generate silent nucleotide substitution or 
non-synonymous substitution. Mutations generating a frame-shift or a premature 
stop codon were not observed. This result is in line with the study by Xin et al 
(2001) and Aho et al. 2004. Both studies have shown that there is no association 
between HPV 52 E6/E7 variants and the development of cervical cancer. 
Current results showed that the nucleotide sequence variability of E7 was higher 
than E6. This observation is different to HPV 16 where the E6 region is more 
variable when compared to E7 (Bontkes, van Duin et al. 1998; Zehbe, Wilander et al. 
1998; Nindl, Rindfleisch et al. 1999; Stephen, Thompson et al. 2000). Moreover, 
previous studies have shown that HPV 16 has a range of variability within the LCR, 
LI, L2, E2, E5 and E7 genes, with E6 being the most variable region (Yamada, 
Wheeler et al 1995; Eriksson, Herron et al 1999). •“ 
A study by Giannoudis et al. (2001) showed that the HPV 16 E6 variant L83V 
was associated with HPV persistence and SILs. Chakrabarti and co-workers (2004) 
showed that there is a relationship between the E6 oncoprotein and activation of 
mitogen-activated protein kinase (MAPK) signaling and show that this signaling 
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involves Rapl. They found that activated MAPK signaling cooperates with 
deregulated Notch 1 signaling to recreate features of HPV-driven invasive cervical 
carcinomas. The variant E6 L83V enhances MAPK signaling and cooperative 
transformation with deregulated Notch 1 signaling. Unlike E6, this variant 
surprisingly inhibits oncogenic Ras-mediated transformation (Chakrabarti, 
Veeraraghavalu et al 2004). However, the same variant was not observed in the 
current study. This finding supported the study by Aho et al (2003) indicating that 
L83V is rarely found in HPV 52. 
The E7 protein has three domains: conserved region 1 (CRl) (amino-terminal 
20 amino acids), CR2 (amino acids 21-40) and CR3 (carboxyl-terminal amino acids 
41-98). Conserved region 1 and 2 are similar to adenovirus El A (Moran and 
Mathews 1987; Phelps, Yee et al. 1988)，CR2 in HPV 16 E7 is involved in binding 
with the pRB and is essential for transformation (Barbosa, Edmonds et al. 1990; 
Bauknecht, Jundt et al 1995) and CR3 contains two zinc binding motifs 
(Cys-Xaa-Xaa-Cys) that are involved in dimerization and protein stability (Mclntyre, 
Frattini et al. 1993). Results from current study showed that seven of nine (78%) 
amino acid substitutions are located in CR3. Amino acid substitution H61Y was 
found within the first zinc binding motif (aa 60-63) indicating that it may have an 
� implication in transformation efficiency. In the zinc binding motifs, reduced 
transforming activity was observed with amino acid substitutions at aa-58 and 91 
(cysteine to glycine) (Edmonds and Vousden 1989). A study by ter Meulen et al 
demonstrated the inability of cysteine mutant to transform cell and zinc binding 
motif but without any change on pRB binding. It has been suggested that cysteine 
mutant could still bind to pRb but this binding was not sufficient for the transcription 
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factor E2F to dissociate (ter Meulen, Schweigler et al. 1993). 
A study by Aho et al. (2004) has reported no single E6- or E7-0RF nucleotide 
substitution was associated with the persistence of HPV 52 infection. However, this 
study also reported that significant association was found between HPV 52 LI 
variants and persistent HPV 52 infection. Therefore, further study on sequence 
variation in HPV 52 LI-ORF is worthwhile, because LI-ORF encodes a major 
capsid protein and it has been suggested that HPV protein variations may reduce the 
host immune system's ability to eradicate HPV, thus leading to the development of 
cervical neoplasia (Giannoudis and Herrington 2001; Aho, Hankins et al. 2003). 
One limitation of this study is the population size. An increase in population 
size will be an advantage to increase the number of samples of each variant. 
Another limitation is the lack of a control group with normal cytology. Age-group 
matched patients without cervical intraepithelial lesions should be collected for 
control samples. So, risk association between human papillomavirus variants and 
cervical neoplasia development can be estimated (Stewart, Eriksson et al. 1996). 
In conclusion, no significant association was found between HPV 52 E6/E7 
‘ variants with the severity of cervical lesions. Further study can be focused on the 
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